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SUMMARY 
 
Insulin and insulin-like growth factor (IGF-1) regulate renal electrolyte excretion and the 
signalling includes PI3-kinase, PDK1, PKB and SGK isoforms. Thus SGK isoforms are 
expected to play a major role in the regulation of renal function which is evident from renal 
phenotype of sgk1-/- mice. 
 
The end effect of PI3-kinase signalling is phosphorylation of GSK3 by PKB/SGK1 
which results in inhibition of its activity. Accordingly, similar/parallel renal phenotype can be 
expected between sgk1-/- mice and gsk3KI mice where GSK3 is resistant to PKB/SGK1 
inhibition. 
 
The first study was made to elucidate the role of GSK3 in renal electrolyte excretion 
and hormone release. The plasma aldosterone and corticosterone concentrations were 
significantly lower while 24-hour urinary aldosterone was significantly higher and urinary 
corticosterone tended to be higher in gsk3KI mice than in gsk3WT mice. The possibility of 
reduced salt appetite due to low aldosterone was checked in gsk3KI mice .The gsk3WT mice 
drank more saline over tap water while gsk3KI mice drank similar amounts of tap and saline 
water. gsk3KI mice display higher metabolic rate with significantly more food and fluid intake, 
fecal excretion, GFR, urinary flow rate and urinary Na+, K+ and urea excretion with lower 
plasma Na+ and urea concentrations and significantly higher blood pressure.  
Enhanced Na+ excretion may at least partially be due to low aldosterone levels which 
should however, not increase but decrease the renal K+ excretion. Thus, a renal mechanism 
involving enhanced ENaC activity presumably causes enhanced renal K+ secretion as Lithium, 
an inhibitor of GSK3 is shown to downregulate ENaC expression. Higher fluid intake 
accounts for higher urinary flow rate but does not reflect decreased urine concentrating 
ability, as urinary osmolarity is increased in gsk3KI mice. Water deprivation did not abrogate 
the differences in urine output. GSK3 may participate in the regulation of renal tubular water 
transport. The unrestrained GSK3 could downregulate NO-synthase which induces thirst. The 
role of GSK3 in eNOS regulation may further contribute to differences in BP. The results thus 
indicate that the renal phenotype of gsk3KI mice is different from the sgk1-/- mice in several 
aspects, thereby suggesting a more direct role of GSK3 in renal electrolyte balance. 
 
APC fosters degradation of ß-catenin which is known to upregulate a variety of 
proteins responsible for tumerogenesis. It was suggested and shown that SGK1 is among the 
proteins that are upregulated. SGK1 expression has also been shown recently to be enhanced 
in gastric glands of apc Min/+ mice. A similar upregulation was expected in the kidneys of 
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these mice and as SGK1 regulates renal electrolyte homeostasis, a possible renal phenotype 
for APC mutant mice was expected. The second study was therefore conducted to explore the 
kidney function in APC mutant mice and thereby elucidate the renal phenotype of those mice. 
The body weight, food, fluid intake and fecal excretion were not significantly different 
between the genotypes. Urine flow tended to be lower in apcMin/+ mice than apc+/+ and 
apcMin/+/sgk1-/- mice. The glomerular filtration rate and Na+ excretion were decreased while 
fractional excretion of K+ was enhanced in apcMin/+ mice. The antinatriuresis and glomerular 
filtration tended to be partially reversed by additional lack of SGK1. Fecal sodium and 
potassium excretion were significantly higher in apcMin/+ mice than in apc+/+ mice. The 
additional lack of SGK1 could reverse the difference in fecal sodium excretion but not the 
fecal potassium excretion.  
The plasma aldosterone and corticosterone concentrations were significantly higher in 
apcMin/+ mice. While plasma corticosterone concentration was similar in apc+/+ mice and 
apcMin/+/sgk1-/- mice, plasma aldosterone was even higher in apcMin/+/  sgk1 -/- mice than in 
apcMin/+ mice. The hyperaldosteronism in apcMin/+ mice was paralleled by elevated plasma 
volume and blood pressure. The difference in plasma volume and blood pressure were slightly 
reversed by additional lack of SGK1. The partial reversal of anti-natriuretic, hypervolemic 
and hypertensive effects in apcMin/+ mice by additional lack of SGK1 implicates its role in the 
abnormal elelctrolyte homeostasis in apcMin/+ mice. SGK1 defeciency augments the effect of 
defective APC on plasma aldosterone indicating a complex interaction of APC and SGK1 or 
independent regulations of APC and SGK1 in hormone release. 
 
The signalling cascade explaining insulin stimulated renal tubular phosphate 
reabsorption remains elusive. Renal phosphate reabsorption is regulated by membrane 
abundance of the phosphate transporter, NaPiIIa and PI3-kinase signalling possibly stimulates 
renal tubular reabsorption by increasing the membrane abundance of NaPiIIa. Again the 
possible role of SGK isoforms could be expected here and the third study thus focussed on the 
regulation of renal phosphate handling by SGK3 which is a downstream kinase in insulin 
signalling. Metabolic studies in sgk3KO mice showed significantly higher phosphate excretion 
in comparision to wild-type mice supporting this hypothesis. Invitro studies involving 
coexpression of SGK3 and NaPiIIa in Xenopus oocytes provided additional evidence by 
showing that phosphate induced current is significantly enhanced in SGK3 and NaPiIIa 
expressing Xenopus oocytes. Food intake was significantly higher in sgk3 KO mice while the 
plasma PTH and plasma phosphate concentrations were similar to sgk3WT mice. Plasma 
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vitamin-D concentration and bone mass were significalty lower. Plasma and urinary calcium 
levels were not different between the genotypes. 
 
These observations reveal a direct role of SGK3 in the phosphate transport and the 
higher phosphate loss and low plasma vit-D in sgk3 KO mice could have contributed to the 
demineralization of the bones in sgk3KO mice. 
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ZUSAMMENFASSUNG 
 
Insulin und Insulin-like-Growth Factor (Insulinähnlicher Wachstumsfaktor, IGF-1) regulieren 
die Elektrolytausscheidung in der Niere. An dieser Signalkaskade beteiligen sich die PI3-
Kinase, PDK1, PKB und verschiedene Sgk-Isoformen. Demzufolge spielen Sgk-Isoformen 
erwartungsgemäß eine bedeutende Rolle bei der Regulation der Nierenfunktion, die für den 
renalen Phänotyp von sgk1-/- Mäusen verantwortlich ist. 
Am Ende der PI3-Kinase Signalkaskade steht die Phosphorylierung der GSK3 durch 
PKB/SGK1. Diese Phosphorylierung hat die Inaktivierung der Kinase zur Folge. Demnach ist 
ein ähnlicher Phänotyp bei sgk1-/- und gsk3KI Mäusen zu erwarten.  
Der erste Teil der Studie sollte die Funktion der GSK3 in Bezug auf Nierenfunktion und 
Hormonregulation aufklären. Die Aldosteron- und Kortisolplasmaspiegel waren signifikant 
erniedrigt. Gleichzeitig konnten signifikant erhöhte Aldosteronkonzentrationen bei den gsk3KI 
im 24-Stunden-Urin gemessen werden. Die Kortisolausscheidung war bei gsk3KI tendenziell 
höher als bei gsk3WT Mäusen. Aufgrund der reduzierten Aldosteronplasmaspiegel wurde 
überprüft, ob gsk3KI Mäuse möglicherweise einen gesteigerten Kochsalzkonsum aufweisen. 
Im Vergleich tranken gsk3WT Mäuse mehr Kochsalzlösung als normales Trinkwasser, 
während gsk3KI Mäuse keine Unterschiede im Trinkverhalten zeigten. gsk3KI Mäuse 
zeichneten sich durch eine gesteigerte von Nahrungs- und Trinkwasseraufnahme, erhöhtes 
Fekalgewicht, sowie eine erhöhte GFR und Urinvolumen, gesteigerte Elektrolyt- (K+ und 
Na+) und Harnstoffausscheidung bei niedrigeren Plasmakonzentrationen von Na+ und 
Kreatinin, sowie signifikant erhöhten Blutdruck aus.  
 Eine gesteigerte Na+-Ausscheidung kann, zumindest teilweise, durch niedrige 
Aldosteronspiegel erklärt werden. Diese sollten ebenfalls die K+-Ausscheidung vermindern 
und nicht erhöhen. Vermutlich ist dies ursächlich durch einen renal stimulierten Mechanismus 
zu erklären, der eine gesteigerte ENaC-Aktivität zur Folge hat. Für Lithium, einen GSK3-
Inhibitor, wurde beispielsweise eine Herunterregulation der ENaC-Expression gezeigt. Eine 
vermehrte Flüssigkeitsaufnahme resultiert in einem größeren Urinvolumen, spiegelt jedoch 
nicht eine verminderte Konzentrationsfähigkeit des Urins durch die Niere wider. Die 
Osmolarität des Urins von gsk3KI Mäusen war dementsprechend erhöht. Flüssigkeitsentzug 
glich den Unterschied in der Ausscheidungsmenge zwischen den Genotypen nicht aus. 
Möglicherweise spielt die GSK3 beim Wassertransport, der durch die Nierentubuli 
gewährleistet wird, eine Rolle. Die nicht-inhibierte GSK3 könnte die NO-Synthase, welche 
Durstgefühl vermittelt, herunterregulieren. Der Einfluss der Kinase auf die NO-Bildung 
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könnte darüber hinaus eine Ursache für den erhöhten Blutdruck der gsk3KI Mäuse sein. Der 
Konsens dieser Ergebnisse deutet auf einen nachweisbaren Unterschied des Nierenphänotyps 
zwischen gsk3KI und sgk1-/- Mäusen hin und lässt die Rolle der GSK3 bezüglich des 
Elektolythaushaltes als bedeutender erscheinen.  
 APC fördert den Abbau von ß-Catenin, welches für die Hochregulation einer großen 
Anzahl an Proteinen, die für die Tumorgenese von Bedeutung sind, wichtig ist. SGK1 
befindet sich nachweislich unter diesen hochregulierten Proteinen. Ebenso konnte bewiesen 
werden, dass die Expression der SGK1 in den Magendrüsen von apcMin/+ Mäusen erhöht ist. 
Ähnliche Regulationsmechansimen hätte man in der Expression der Nieren dieser Mäuse 
erwartet, und, da bekannt ist, dass SGK1 die renale Elektrolytausscheidung reguliert, auch 
einen möglicher relevanter Nierenphänotyp. Der zweite Teil dieser Studie wurde daher der 
Exploration der Nierenfunktion von APC-defekten Mäusen gewidmet. Köpergewicht, 
Nahrungs- und Trinkverhalten und Fekalvolumen war nicht unterschiedlich. Das 
Urinvolumen erschien bei den apcMin/+ Mäusen niedriger als bei den apcMin/+ und 
apcMin/+/sgk1-/- Mäusen. Die glomeruläre Filtrationsrate und Na+-Ausscheidung waren 
erniedrigt während die fraktionelle K+-Ausscheidung bei den apcMin/+ erhöht war. Die 
verminderte GFR und Exkretion von Na+ wurde teilweise durch die Abwesenheit der SGK1 
(apcMin/+/sgk1-/-) aufgehoben. Der Na+ und K+-Gehalt in den Feces waren bei den apcMin/+ im 
Vergleich zu den apcMin/+ Mäusen signifikant erhöht. Die verminderte Na+-Ausscheidung 
wurde durch den zusätzlichen Mangel an SGK1 egalisiert während die K+-Ausscheidung im 
Stuhl unverändert blieb. 
 Die Konzentrationen an gemessenen Aldosteron- und Kortisolspiegeln im Plasma 
waren bei den apcMin/+ signifikant erhöht. Die Kortisolplasmakonzentrationen der apcMin/+  
und apcMin/+/sgk1-/- Mäusen waren gleich, die Aldosteronkonzentration war bei den 
apcMin/+/sgk1-/- sogar höher als bei den apcMin/+ Mäusen. Der Hyperaldosteronismus der 
apcMin/+ Mäuse ging einher mit einem gesteigerten Plasmavolumen sowie einem erhöhtem 
Blutdruck, beides wurde durch einen zusätzlichen Mangel an SGK1l zu einem gewissen Grad 
normalisiert. Die partielle Aufhebung der antinatriuretischen, hypervolämischen und 
hypertensiven Effekte bei den apcMin/+/sgk1-/- Mäusen lässt einen Zusammenhang zwischen 
einem SGK1-knock-out und dem veränderten Elektrolythaushalt der apcMin/+ Mäuse 
vermuten. Das Fehlen von SGK1 erhöht die Auswirkung von nicht-funktionellem APC auf 
die Plasmaaldosteronkonzentration und deutet auf eine komplexe Interaktion zwischen APC 
und SGK1 hin. Eine unabhängige Hormonregulation durch APC und SGK1 ist ebenfalls 
denkbar und daher in Betracht zu ziehen. 
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 Die Signalkaskade, welche die Insulin stimulierte renal-tubuläre 
Phosphatrückresorption erklären könnte, bleibt unklar. Die Phosphatrückresorption in der 
Niere wird durch die Anwesenheit von Phosphattransportern (NaPiIIa) in der Membran 
reguliert. Die PI3-Kinasekaskade stimuliert möglicherweise diese Rückresorption, indem die 
Menge des NaPiIIa in der Membran hochreguliert wird. Auch hier wäre ein möglicher 
Einfluss der SGK-Isoformen denkbar, daher fokussierte der dritte Teil der Studie die Wirkung 
der SGK3, eine Kinase innerhalb der Insulinsignalkaskade, auf den renalen Phosphattransport. 
Untersuchungen an SGK3-defizienten (sgk3-/-) Mäusen zeigten eine signifikant erhöhte 
Phosphatausscheidung. Dieser Befund unterstützte die These einer möglichen Beteiligung der 
Insulinsignalkaskade an der renalen Phosphatregulation. Voltage clamp Untersuchungen, die 
in vitro Experimente an Oozyten beinhalteten, zeigten, dass die Koexpression von SGK3 und 
NaPiIIa in den Oozyten den Phosphatausstrom aus den Zellen signifikant erhöhte. Die 
Nahrungsaufnahme war bei sgk3-/- Mäusen signifikant erhöht. Die Konzentrationen von 
Parathormon und Phosphat im Plasma ähnlich deren von sgk3+/+ Mäusen. Die 
Plasmakonzentration von Vitamin D und die Knochenmasse waren bei den sgk3+/+ Mäusen 
signifikant vermindert. Die Calciumkonzentration im Plasma und Urin unterschieden sich 
nicht. 
 Diese Befunde decken einen direkten Einfluss der SGK3 auf den Phosphathaushalt 
und dessen Regulationsmechansimen, der den Vitamin D-Haushalt und die 
Knochenmineralisierung beeinträchtigt, auf.
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INTRODUCTION 
 
KIDNEY 
 
Kidneys are primarily responsible for the maintenance of body fluid homeostasis, which is 
achieved by regulating the volume and concentration of body fluids by selectively filtering 
and reabsorbing materials from the blood and urine. Neural and endocrine systems acting on 
kidneys from outside the excretory system along with auto-regulatory mechanisms of kidneys 
regulate the functional processes and thus help in the homeostasis. 
The main functions of kidney include: 
• Regulation of water and electrolyte content of the body. 
• Retention of substances vital to the body such as protein and glucose 
• Maintenance of acid/base balance. 
• Excretion of waste products, water soluble toxic substances and drugs. 
• Endocrine functions 
 
Water and electrolyte balance 
 
Water content of the body is maintained by regulating the osmalality of body fluids. Loss of 
fluid through lungs or skin increases while fluid intake decreases the osmalality. Kidney 
regulation of water excretion through antidiuretic hormone (ADH) maintains the osmotic 
pressure of the extracellular fluid (ECF) by negative feedback mechanism. The osmoreceptors 
located in the anterior hypothalamus are sensitive to the changes in intracellular volume or 
changes in osmotic concentration. With a rise in ECF osmotic concentration, the impulses 
from the receptors are transmitted to the secretory neuron endings in the posterior pituitary 
which triggers ADH release. The released ADH increases water reabsortion and continues 
solute excretion reducing the osmotic concentration of the ECF providing the negative 
feedback to osmoreceptors which in return induce fall in the rate of ADH release. 
  
The hormones interact when blood loss or dehydration occurs to maintain 
intravascular volume. 
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Excretion of waste products 
 
Filtration occurs as blood flows through the glomerulus. Metabolic wastes and drugs that 
cannot be filtered by the glomerulus are secreted into the tubule and excreted in the urine. 
 
Regulation of Acid-Base balance 
 
The body is very sensitive to its pH level. Alterations in the pH causes protein denaturation 
and loss of function of enzymes. The kidneys maintain acid-base homeostasis by regulating 
the pH of the blood plasma. 
The lungs and kidneys work together to maintain constant pH of 7.35 - 7.45 (34-46 
nmol.l-1 H+ concentration) in the extracellular fluid and arteries. The two buffer systems are 
in dynamic equilibrium with the same hydrogen ion concentration (pH). The lungs assist in 
maintaining a constant blood pH by removing CO2, while the kidney excretes acid in the form 
of H2PO4- and NH4+ and alkali in the form of HCO3-. 
 
Regulation of BP 
 
 
The kidney influences blood pressure by: 
 
    * Constriction and dilatation of arteries and veins  
    * Increasing the circulating blood volume 
 
Specialized cells called macula densa located in a portion of the distal tubule and in the wall 
of the afferent arteriole sense the Na+ in the filtrate and the arterial cells (juxtaglomerular 
cells) sense the blood pressure. When the blood pressure drops the juxtaglomerular cells sense 
it and convey to the macula densa cells leading to decrease in amount of Na+ filtered. The 
juxtaglomerular cells then release an enzyme called renin. Renin converts angiotensinogen 
into angiotensin I which is then converted to angiotensin II by an angiotensin-converting 
enzyme (ACE) that is found mainly in the lungs. Angiotensin II causes blood vessels to 
contract and thus elevates the blood pressure Figure 1. 
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Figure 1 A simplified flow chart of blood pressure regulation by the kidney. 
 
 
Endocrine regulation and homeostasis 
 
Aldosterone hormone  regulation of sodium and potassium  
 
The kidneys play a central role in the maintenance of Na+ homeostasis. It is important to 
tightly regulate the urinary Na+ excretion in order to maintain a constant extracellular volume 
during varying dietary Na+ intake and extrarenal Na+ losses. The final concentration of renal 
Na+ that is excreted is controlled by the ASDN (aldosterone sensitive distal nephron) which 
includes the late distal convoluted tubule, the connecting tubule and the cortical (CCD) as 
well as the medullary (MCD) collecting ducts 1. Na+ entry into the epithelial cells via the 
epithelial Na+ channel (ENaC) in the luminal membrane and exit through the Na+,K+-ATPase 
in the basolateral plasma membrane accomplishes the transepithelial Na+ transport in these 
segments. The rate-limiting step in this process is ENaC which is highly regulated 2. It is 
composed of three subunits (α, β, and γ) 3-6 with a stoichiometry of 2α1β1γ 7, although other 
stoichiometries have also been suggested (octa- or nonamers) 8;9. Mutations in the genes 
encoding ß- and γ-ENaC leads to Liddle’s syndrome, an inherited form of salt-sensitive 
hypertension 10. The PY motifs of ENAC sub-units are the binding sites for ubiquitin protein 
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ligases of Nedd4/Nedd4-2 like family 11-13. Binding to these motifs ubiquitylates ENAC on α 
and γ sub-units consequently leading to the internalization and degradation of ENaC in the 
endosomal/lysosomal system 14;15. 
 
Apart from its stimulatory effect on renal Na+ reabsorption, aldosterone has strong 
kaliuretic action. The renal outer medullary K+ channel (ROMK) regulates the K+ secretion 
occurring in ASDN. ROMK is coexpressed with ENaC in the ASDN cells and the necessary 
driving force for K+ secretion is provided by the Na+ reabsorption. Inhibition or genetic loss 
of function of ENAC lowers renal K+ secretion leading to hyperkalemia. However, it remains 
unresolved whether the kaliuretic effect of aldosterone is through direct regulation of ROMK 
function or by Na+ reabsorption via ENAC activation. No measurable effect of acute 
aldosterone administration on K+ channel number, open probability or conductance was found 
by patch-clamp studies on rat CCDs 16;17, but some data suggested that aldosterone induces 
renal K+ secretion already at aldosterone concentrations that do not exhibit any measurable 
effect on urinary Na+ excretion 18. Moreover, high K+ intake results in more efficient increase 
in ROMK activity in intact rats than in adrenalectomized animals, suggesting that aldosterone 
may have at least a permissive effect on ROMK activation 16.  
 
Parathyroid hormone and calcium and phosphate regulation  
 
Parathyroid hormone (PTH) is responsible for the endocrine regulation of calcium and 
phosphate. Decrease in blood levels of calcium stimulates the production of PTH, which has 
physiological effects on the kidneys. 
 
In the kidneys the parathyroid hormone increases calcium reabsorption in the renal 
distal tubules, while it inhibits phosphate reabsorption in proximal tubules and thus forces 
renal phosphate wasting. 
Phosphate homeostasis 
 
 
Phosphate (Pi) homeostasis in higher organisms depends on the coordinated transport of Pi 
across intestinal and renal epithelia. Transport of Pi across the apical membrane is mediated 
by the three members of the SLC34 family of solute carriers referred commonly as ‘NaPi’ 19. 
NaPiIIa (SLC34A1) and NaPiIIc (SLC34A3) are specifically expressed in the brush border 
membrane (BBM) of renal proximal tubules whereas NaPi-IIb (SLC34A2) has a broader 
pattern of expression and is highly abundant in the BBM of small intestine. The transporter 
mediating the basolateral Pi exit in both renal and intestinal epithelia is unidentified. Na+-
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dependent electroneutral anion exchanger has been proposed to be at least partially 
responsible for Pi exit in the proximal tubule 20. 
 
NaPiIIa and NaPiIIc mediate the reabsorption of Pi from the urine by using the free 
energy provided by the electrochemical gradient for Na+. NaPiIIa is electrogenic and it 
preferentially transports divalent Pi with a strict Na+-Pi stoichiometry of 3:1, which results in 
the net inward movement of one positive charge per cotransport cycle. In contrast, NaPiIIc is 
electroneutral and functions with a 2:1 stoichiometry (Figure 2) 21;22. In mice, NaPi-IIa is the 
main phosphate transporter in the adult kidney, whereas NaPiIIc appears to be more important 
in weaning animals. This was further confirmed by the phenotype of NaPiIIa knockout mice 
which suggested that this cotransporter is responsible for the bulk of renal Pi reabsorption 
with a very small percentage potentially attributed to NaPi-IIc 23. The expression of NaPiIIa 
and NaPiIIc is regulated to adapt the renal reabsorption of Pi to the needs of the organism. 
Thus, the phosphaturic effect associated with parathyroid hormone (PTH) is due to the 
membrane retrieval of both cotransporters, whereas in conditions of Pi deprivation their 
expression is increased 24-26. 
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Figure 2: Mechanisms of phosphate transport. 
Introduction                                                                                                                           IV 
 13 
 
 
Many hormonal and non-hormonal factors also regulate renal Pi reabsorption and the effect of 
PTH and dietary Pi on NaPi-IIa has been investigated in detail 27. These studies suggest that 
regulation of NaPi-IIa depends on its shuttling to/from the BBM. This contrasts with many 
other transporters, whose activity is modulated by modification of the transport protein itself 
(e.g. phosphorylation, dimerization etc). This means that the body's requirements for a higher 
Pi reabsorption (i.e. after low Pi-diet) are met by increasing the expression of NaPiIIa 24;28;29 
and NaPiIIc 21 at the BBM. Acute upregulation of NaPiIIa is thus independent of changes in 
transcription or translation and the increased expression of NaPiIIa must be due to either the 
stabilization of the transporter at the BBM 30 or to an increased rate of insertion at the 
membrane 28.  
 
On the other hand, reduced reabsorption of Pi (i.e. upon PTH release or high Pi-diet) is 
achieved via downregulation of NaPiIIa 25;28;31 and NaPiIIc 26 at the BBM. PTH-induced 
downregulation of NaPiIIa has been studied extensively and the identifiable steps are 
summarized in Figure 2.  
 
SGK1      
 
Serum and glucocorticoid-inducible kinase, an inducible Ser/Thr Kinase, (sgk1) was 
originally isolated in a differential screen searching for glucocorticoid-induced transcripts in a 
mammary tumor cell line 32. It was found to be induced within 30 minutes, either by 
glucocorticoids or by serum and in both mammary epithelial cells and fibroblasts. SGK1 
belongs to AGC kinases family, which include protein kinase A (PKA), protein kinase G 
(PKG), protein kinase C (PKC), and protein kinase B/Akt/rac (PKB/Akt). Its catalytic domain 
shares 54% identity with those of Akt/PKB/rac kinases, 48% with that of PKC-β, 50% with 
that of rat p70S6K kinase and 45% with that of PKA. 
 
SGK1 is also induced by a very large spectrum of stimuli distinct from glucocorticoids 
and serum. These include aldosterone 33;34, cell shrinkage 35;36, cell swelling 37, TGF-β 38-41, 
ischemic injury of the brain 42;43, neuronal excitotoxicity 44, memory consolidation 45, chronic 
viral hepatitis 40, DNA-damaging agents 46, vitamin D3 47, psychophysiological stress 48, iron 
49
, glucose 41, endothelin-1 41, granulocyte-macrophage colony–stimulating factor (GM-CSF) 
50
, fibroblast growth factor (FGF) 51, platelet-derived growth factor (PDGF) 51, phorbolesters 
51
, follicle-stimulating hormone (FSH) 52, sorbitol 46;53, heat shock, oxidative stress, UV 
irradiation and p53 46;53. 
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SGK1 is phosphorylated on Ser422 in the C-terminal region by a so far unknown 
kinase termed the hydrophobic motif (H-motif)/PDK2 that is dependent on PI3 Kinase 
signalling. SGK1 is an unstable protein with a rapid turnover and a half-life of approximately 
30 minutes. Rapid degradation of SGK1 involves its ubiquitylation followed by degradation 
by the proteosome. Moreover, it appears that ubiquitylated SGK1 is preferentially associated 
with intracellular membranes 54  
Target Proteins 
 
SGK1 was shown to phosphorylate a variety of proteins. The first demonstrated substrate for 
SGK1 was glycogen synthase kinase 3 (GSK3), a kinase that is involved in the regulation of 
glycogen and protein synthesis by insulin and that is also a substrate of PKB/Akt 55;56. 
Phosphorylation of GSK3 by both SGK1 and PKB/Akt leads to an increase in the synthesis of 
glycogen. 
 
Role of SGK1 in Aldosterone-Dependent Na+ Reabsorption 
 
SGK1 can directly interact with ENaC 57 and increase ENaC channel activity by 
phosphorylating the α-ENaC subunits. The action of SGK1 on ENaC is complex and likely 
involves (a) increase in the subunit abundance in the plasma membrane and (b) activation of 
channels already in the plasma membrane combined with an increase in ENaC opening 
probability. 
 
As an aldosterone-induced protein, SGK1 is thought to mediate at least some of the 
physiological effects of aldosterone on ENaC and Na+,K+-ATPase. The stimulatory effect of 
aldosterone (or of dexamethasone) on SGK1 expression has now been firmly documented and 
extensively reviewed 58. Corticosteroids rapidly (within 30 minutes) induce SGK1 at the 
mRNA and/or protein levels. This induction coincides with enhanced phosphorylation of 
Nedd4-2 and reduced renal Na+ secretion in intact animals. The physiological importance of 
aldosterone in SGK induction is supported by the fact that dietary Na+ restriction, which 
physiologically increases plasma aldosterone, also induces SGK1 mRNA in the renal cortex 
59
. The aldosterone-dependent induction of SGK1 occurs specifically in the ENaC-positive 
cells of the ASDN, whereas in other nephron portions such as the thick ascending limb or the 
proximal tubule SGK1 expression is not increased by aldosterone 58. 
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Figure 3: Proposed interaction between SGK1, epithelial Na+ channel (ENaC) and renal outer medullary 
K+ channel (ROMK) in aldosterone-sensitive distal nephron. 60 
Aldosterone stimulates the expression of ENaC, ROMK and SGK1. Activation of SGK1 (Sgk1a) requires 
phosphorylation of the kinase, which, in addition to other factors, can be induced by binding of insulin (Ins) or 
arginine vasopressin (AVP) to their basolateral receptors. Sgk1 is not absolutely required for insertion of ENaC 
or ROMK into the apical membrane, explaining the mild phenotype of SGK1-deficient mice under standard 
NaCl and K+ diet. SGK1-dependent upregulation of Na+ reabsorption, however, is required under reduced 
dietary NaCl intake as well as for upregulation of renal K+ excretion in response to increased dietary K+ intake. 
SGK1a increases Na+ reabsorption by activating Na+-K+-ATPase and enhancing the abundance in the cell 
membrane of ENaC through inhibition of ubiquitin ligase Nedd4–2 mediated internalization of ENaC. Effects of 
SGK1a on ENaC and Na+-K+-ATPase increase the electrical driving force for paracellular Cl- reabsorption as 
well as the electrochemical driving force for K+ secretion through ROMK. In addition, SGK1 may enhance the 
abundance of ROMK in the apical membrane by synergizing with NHERF2. MR, mineralocorticoid receptor; 
PKA, protein kinase A; PDK, 3-phosphoinositide-dependent kinase. 
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Mouse phenotype 
 
The SGK1-deficient mice exhibiting rather a mild phenotype points to a certain degree of 
redundancy in SGK1-dependent signal transduction cascades. SGK1 mice have no obvious 
defect 61. Closer analysis reveals the decreased ability of SGK1 knockout mice to retain salt 
under a salt-deficient diet 61 or to adequately enhance renal K+ output during a K+ load 62. 
Presumably due to salt depletion, plasma aldosterone concentration is enhanced 61 and renal 
Ca2+ excretion is decreased 63. The mice are relatively resistant to the hypertensive effect of a 
high-fructose diet 64 or a high-fat diet 65 together with salt excess. In the SGK1 knockout 
mice, the stimulating effect of mineralocorticoids on salt appetite 66 and the stimulating effect 
on intestinal glucose uptake 67 is blunted and the uptake of glucose into brain, adipocytes and 
skeletal muscle following a glucose load is decreased 68. 
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GSK3 
 
Glycogen synthase kinase 3 (GSK3) was originally identified as one of five protein kinases 
that phosphorylate the rate-limiting enzyme glycogen synthase (GS) of glycogen synthesis in 
response to insulin 69. GSK3 is a serine threonine kinase encoded by two isoforms GSK-3α 
and GSK-3β 70.  
 
GSK3 is ubiquitously expressed and evolutionarily conserved kinase 71. In addition to 
GS,GSK3 phosphorylates a broad range of substrates, including several transcription factors 
such as c-Myc, c-Jun and c-Myb 72 and the translation factor eIF2B 73. GSK3 has also been 
implicated in the regulation of cell fate in Dictyostelium 74 and is a component of the Wnt 
signalling pathway required for Drosophila and Xenopus development 75. In mammalian cells, 
on stimulation with insulin or other growth factors, GSK3 is rapidly phosphorylated at serine 
21 in GSK-3α or serine 9 in GSK-3β, resulting in inhibition of GSK3 kinase activity 76. 
Protein kinase B (PKB/Akt), a serine-threonine kinase located downstream of 
phosphatidylinositol 3-kinase (PI3K), has been demonstrated to phosphorylate both of these 
sites in vitro and in vivo, suggesting that growth factors downregulate GSK3 activity through 
the PI3K–PKB signalling cascade 56. Consistent with its position downstream of the PI3K–
PKB pathway, GSK3 activity suppresses cell proliferation and survival. 
 
Regulation of GSK3 by the Wnt pathway  
 
In multicellular organisms, GSK3 functions in several distinct signalling pathways. Activation 
of any of these pathways leads to inactivation of GSK3 kinase activity by one of the three 
distinct mechanisms: (i) inhibition by the action of Dishevelled, (ii) NH2-terminal domain 
serine phosphorylation or (iii) tyrosine phosphorylation. 
 
 
In the absence of a Wnt signal, GSK3 interacts with β-catenin, axin and APC in the 
cytoplasm and phosphorylates these proteins, leading to the Slimb/βTrCP-mediated 
ubiquitination and proteolytic degradation of β-catenin. Upon binding of Wnt by a seven-
transmembrane domain receptor, dishevelled is activated resulting in the downregulation of 
GSK3 kinase activity 77(Figure 4). 
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Regulation of GSK3 by other signalling pathways 
 
GSK3 phosphorylates GS at four distinct sites. Inhibition of GSK3 causes activation of 
glycogen synthase due to less phosphorylation leading to conversion of glucose into glycogen. 
Stimulation of glycogen synthesis by insulin also involves the dephosphorylation of serine 
residues in glycogen synthase.  
 
Several signalling mechanisms independent of Wnt have been proposed to explain 
inhibition of GSK3. Some studies support the involvement of mitogen-activated protein 
kinase (MAPK) in GSK3 regulation.  
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Figure 4: Role of GSK3 in phosphatidylinositol 3-kinase signalling.  
Upon receptor tyrosine kinase activation, PI3 kinase is recruited to the plasma membrane and phosphorylates 
phosphoinositides at the 3‘-position of their inositol ring. This, in turn, recruits PH-domain-containing proteins 
such as PKB and the PDKs. Once phosphorylated by the PDKs, PKB is activated and phosphorylates GSK-3 
leading to its inhibition.  
 
GSK3 inhibition 
 
GSK3 can be inhibited by Akt phosphorylation, which is part of insulin signal transduction. 
Therefore, Akt is an activator of many of the signalling pathways blocked by GSK3 
Experimentally, it has been shown that certain concentrations of lithium chloride (LiCl) 
and/or 6-bromoindirubin-3'-oxime (BIO) will inhibit GSK3 78 in the Wnt signalling pathway. 
This inhibition of GSK3 is currently believed to underlie the therapeutic usefulness of lithium 
salts for the treatment of mood disorders 79. GSK3 phosphorylation by PKC kinases in 
hemopoietic cells regulate growth 80.  
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Mouse phenotype 
 
Dario R. Alessi generated GSK3 knockin mice in which the codon encoding Ser21 of 
GSK3alpha and Ser9 of GSK3beta was changed to encode a non-phosphorylatable Alanine 
residue. The GSK3 knockin mice display no overt phenotype. GSK3 knockin mice develop 
and grow normally (shown by growth curves from 4-16 weeks of age) and are non-diabetic.  
These mice can dispose of injected glucose at the same rate as wild type mice. They possess 
normal fasted glucose and insulin levels 81. 
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APC 
 
The adenomatous polyposis coli (APC) gene was identified by positional cloning in 1991. 
APC is a large gene, encompassing 15 exons with an open reading frame of 8,538 base pairs. 
It encodes a protein of 2,843 amino acids with a molecular weight of 310kD. APC is 
classified as a tumor suppressor gene, since inactivation of both alleles results in the loss of 
control of cell growth and proliferation. Patients with FAP have a germ-line mutation in one 
of the two alleles of the APC gene. These mutations result from point mutations, insertions or 
deletions that lead to a premature stop codon and a truncated functionally inactive protein 82. 
More than 300 different APC mutations have been described 83. 
 
The APC gene product is widely expressed in many tissues, including brain, eye, 
esophagus, stomach and liver tissues. Its structure is characterized by numerous functional 
domains which mediate protein-protein interactions in cell adhesion, the formation of 
epithelial cell-cell contacts, regulation of ß-catenin and maintenance of cytoskeletal 
microtubules 84. 
 
APC in WNT pathway 
 
 
WNT acts as a ligand for a 7-pass transmembrane Frizzled receptor. When WNT is absent, ß -
catenin is ubiquinated and degraded by the proteosomal pathway, resulting in low levels of ß-
catenin. WNT absence allows DSH to activate GSK3, which then phosphorylates ß-catenin, 
followed by its ubiquination by TrCP and proteosomal degradation. This involves a 
multiprotein destruction complex composed of APC, AXIN, GSK3, and TrCP. A LEF/TCF 
transcription factor together with cofactors CBP, CtBP, and Groucho repress target genes. 
When WNT is present, DSH inhibits phosphorylation of ß-catenin by GSK3. This results in 
excess ß-catenin which translocates to the nucleus and together with LEF/TCF, upregulates 
target genes. Regulation of ß-catenin is essential for the tumor suppressor effect of APC. This 
can be circumvented by mutations in either APC or ß-catenin, resulting in familial 
adenomatous polyposis. 
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Figure 5: A simplified illustration of canonical WNT pathway. 
 
 
Mouse Phenotype 
 
Mice homozygous for the Min mutation die as embryos, while heterozygous mice develop a 
severe phenotype characterized by numerous small intestinal adenomas and mammary tumors 
85
. Two different APC mutant mice having mutations at codon 1638 were generated by gene 
targeting. APC 1638N heterozygous mice that have a much milder phenotype (five to six 
small intestinal tumors per mouse) and APC1638T heterozygous mice that do not develop 
intestinal tumors 86;87. A fourth mouse model, APC d716, develops 200 to 500 intestinal 
adenomas. 
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SGK3 
 
Serum and glucocorticoid inducible protein kinase 3 (SGK3) is an isoform of SGK like 
SGK2. SGK2 and SGK3 share 80% amino acid sequence identity in their catalytic domains 
with each other and with SGK 88. For these reasons, SGK has been termed SGK1. SGK3, also 
termed cytokine-independent survival kinase (CISK) 89, is distinguished by an NH2-terminal 
PX (Phox) domain. Like SGK1, SGK3 is expressed in all human and murine tissues 
examined, but expression is particularly high in the mouse heart and spleen and in the 
embryo. SGK3 appears to be localized to vesicular compartments in transfected 293 cells. 
This localization is dependent on the PX domain, the removal of which by truncation of the 
NH2 terminus results in diffuse staining of SGK3 throughout the cell 89. 
 
Regulation of SGK3 kinase activity 
 
SGK3 protein kinase becomes functional after activation by phosphorylation, which is 
accomplished through a signalling cascade involving PI3-kinase, PDK1 and PDK2 or 
"hydrophobic motif" (H-motif) kinase 55;90. Degradation of PIP3 by phosphatase and PTEN 91 
leads to the disruption of activation of the SGK3. SGK3 is also activated by oxidation, insulin 
and IGF-I through the same signalling cascade. 
 
Functions 
Ion channels 
 
Like sgk1, sgk3 regulates many ion channels like the Epithelial Na+ channel-ENaC 1, renal 
epithelial Ca2+ channel-TRPV5 92 , renal and inner ear Cl– channel-ClC-Ka 93, ubiquitous Cl– 
channel-ClC2 94, cardiac voltage-gated Na+ channel-SCN5A 95, cardiac and epithelial K+ 
channels-KCNE1/KCNQ1 96, voltage-gated K+ channels-Kv1.3, Kv1.5 97 and Kv4.3, and  
amino-3-hydroxy-5-methyl-4-isoxazolic acid (AMPA) receptor 98.  
 
Carriers and Pumps 
 
SGK3 has been shown to upregulate amino acid transporters like EAAT1 and EAAT5 99;100. 
Na+-dicarboxylate cotransporter NaDC-1 is stimulated by SGK1 and SGK3, an effect 
requiring the participation of NHERF2 101. Both SGK1 and SGK3 stimulate the activity of 
Creatine transporter-CreaT (SLC6A8) 102. SGK3 modulates Na+-K+-ATPase activity (Henke 
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et al., 2004). In Xenopus oocytes, SGK3 has been shown to stimulate the activity of the Na+-
glucose cotransporter SGLT1 103, which serves to absorb intestinal glucose. 
 
SGK3 has been shown to confer cell survival 89. The antiapoptotic effect of SGK3 has 
been attributed in part to its ability to phosphorylate forkhead transcription factors, such as 
FKRHL189. Moreover, SGK3 has been shown to phosphorylate and thus inactivate Bad 104. 
Phosphorylated Bad binds to the chaperone 14–3-3 and is thus prevented from traveling to the 
mitochondria, where it triggers apoptosis 105. 
 
Mouse phenotype 
 
The phenotype of SGK3 knockout mice is surprisingly mild. SGK3 null mice do not exhibit 
any of the phenotypes associated with the various reported PKB knockout mice 106. Mice 
lacking SGK3 are viable and fertile and display a defect in post-natal hair follicle 
development. Starting at post-partum day 4 (PP4), a clear difference in hair follicle 
progression can be observed which becomes more pronounced in later stages. In addition, the 
hair follicle of the knockout animals is disorganized, suggesting that SGK3 may also be 
involved in cell differentiation and migration. SGK3 null mice also show a transient growth 
defect until 7 weeks of age 106. This delayed growth may be due to a decrease in intestinal 
glucose transport through the sodium-dependent glucose transporter SGLT1 107. Closer 
inspection of the SGK3 knockout mice revealed a subtle decrease of locomotion 60. 
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AIMS OF THE STUDIES 
 
The present studies aimed at identifying the role of three different kinases involved in various 
renal epithelial transport mechanisms and their regulation in hormone secretion.These include 
the following 
 
a) The role of PKB/SGK resistant GSK3 in renal water and electrolyte excretion as well 
as steroid hormone release. 
b) SGK1 dependence of renal electrolyte balance and hormone regulation in APC min 
mice. 
c) The role of SGK3 in renal phosphate handling. 
 
Rationale for the present studies 
 
a) The role of PKB/SGK resistant GSK3 in renal water and electrolyte 
excretion as well as steroid hormone release 
 
GSK3 activity is inhibited by insulin 108;109, an effect mediated by protein kinase B 56;110 and 
the serum and glucocorticoid inducible kinase SGK 111.  
 
At least in theory, inhibition of GSK3 could contribute to SGK1 dependent effects of 
insulin on renal electrolyte transport. Insulin stimulates the renal epithelial Na+ channel ENaC 
and thus leads to renal retention of NaCl 112-114. The effect of insulin on ENaC involves the 
Phosphatidylinositide-3 (PI3)- kinase 115-117 and the serum and glucocorticoid inducible kinase 
SGK1 33;34;118. Whether or not the effects of SGK1 on ENaC 33;34;119 and further renal tubular 
transport systems 60 involves regulation of GSK3, has never been addressed.  
 
Moreover, GSK3 could participate in the insulin like growth factor (IGF)-dependent 
regulation of aldosterone and cortisol synthesis 120.  
 
The first study explored, whether phosphorylation and inactivation of GSK3 could 
participate in the regulation of renal tubular electrolyte transport and steroid hormone release. 
To this end aldosterone and cortisol release as well as renal electrolyte excretion were 
analysed in mice carrying mutations of GSK3α,ß (gsk3KI), in which the serines of the PKB 
phosphorylation sites were replaced by alanine 81. Those mice have previously been shown to 
lack the known effect 81;121 of insulin on muscle glycogen synthase 81. Steroid hormone 
release and renal electrolyte excretion, have, however, not been analysed in those mice. 
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b) SGK1 dependence of renal electrolyte balance and hormone regulation in 
APC min mice 
 
Lack of APC leads to accumulation of ß-catenin, which travels into the nucleus and triggers 
the expression of several genes 122;123 including the serum and glucocorticoid inducible kinase 
SGK1 124;125. As shown in gastric glands 126, SGK1 expression may indeed be enhanced in 
those mice. Among other targets, SGK1 phosphorylates glycogen synthase kinase 3 (GSK3) 
111
, which in turn phosphorylates ß-catenin and is thus involved in APC-dependent regulation 
of cellular functions 127-129. SGK1 is a stimulator of a wide variety of renal transport proteins 
60
. Moreover, lack of SGK1 leads to an increase of plasma mineralocorticoid concentration 61.  
 
 The present study was thus performed to elucidate whether adrenal hormone levels 
and/or electrolyte homeostasis are altered in apcMin/+ mice and if so whether the difference 
may be dependent on the presence of SGK1. To this end, metabolic cage experiments were 
performed in apcMin/+ mice, in their wild type littermates (apc+/+) and in apcMin/+ mice lacking 
in addition SGK1 (apcMin/+/sgk1-/-). 
 
c) The role of SGK3 in renal phosphate handling 
 
Phosphate is a critically important component of bone minerals 130;131. Accordingly, adequate 
mineralization of bone depends on the precise tuning of phosphate balance, which is a 
function of intestinal absorption and renal excretion 130;132;133. The latter depends on cellular 
uptake of phosphate across the apical membrane of proximal tubular cells 134, which is 
accomplished mainly by the Na+-coupled phosphate transporter NaPiIIa 132;134. The carrier is 
downregulated by parathyroid hormone PTH 132, a hormone at least in part effective through 
cAMP. Renal tubular phosphate reabsorption is stimulated by insulin 135;136 and by insulin-
like growth factor IGF-1 137. Little is known, however, about the signalling involved in insulin 
and IGF-1 mediated regulation of phosphate excretion.  
 
The signalling of insulin involves the serum and glucocorticoid-inducible kinase 
SGK3 88, which, similar to protein kinase B 138 and SGK1 55, is activated through 
phosphatidylinositol (PI)-3 kinase and phosphoinositide-dependent kinase PDK1.  
 
The present study thus explored the possibility that SGK3 may be involved in the 
regulation of renal tubular transport. To this end, in vitro regulation of NaPiIIa by SGK3 was 
studied in the Xenopus oocyte expression system and in vivo significance of SGK3-sensitive 
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phosphate transport elucidated by analyzing gene targeted mice lacking functional SGK3 
(sgk3KO) as well as their wild type littermates (sgk3WT) . 
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MATERIALS  
 
Equipment  
  
Accucheck Sensor Comfort   (Roche Diagnostics, Manheim, Germany)  
Balance     (Sartorius, Göttingen, Germany)  
BioPhotometer Eppendorf   (Eppendorf, Wesseling-Berzdorf, Germany)  
Centrifuge 5417 R   (Eppendorf, Hamburg, Germany)  
Dri-chem clinical chemistry analyzer (FUJI FDC 3500i, Sysmex, Norsted, Germany). 
Flame photometry    (AFM 5051, Eppendorf, Hamburg, Germany)  
Gamma Counter    (Perkin Elmer, Massachusetts, USA)  
Heparinized capillaries  ( Hirschmann laborgerate,Eberstadt,Germany) 
Hot air oven    ( Memert,Schwabach,Germany) 
High resolution microCAT-II  (Siemens, Germany) 
Magnetstirrer     (IKA, Staufen, Germany)  
Metabolic cages    (Techniplast, Hohenpeissenberg, Germany)  
Multireactiontubes    (Eppendorf, Hamburg, Germany)  
MultiChanelPipet    (Eppendorf, Hamburg, Germany)  
Multilevel counter    (Victor 1420, PerkinElmer, Boston, USA)  
Osmometer     (Osmomat 030, Gonotec, Berlin, Germany) 
Petri dishes     (Greiner Bio-one, Frickenhausen, Germany)  
Pipettes     (Eppendorf, Hamburg, Germany)  
Pipette tips     (Carl Roth, Karlsruhe, Germany)  
Shaker VIBRAX VXR             ( IKA, Staufen, Germany)  
Spectronic GENESYS 6   (Thermo Fisher Scientific Inc. Massachusets, USA)  
SpeedVac SVC 100    (Savant Life Sciences, Bath, UK)  
Sterile PS-tube 4.5 ml 12.4/75 MM  (Greiner bio-one, Frickenhausen, Germany)  
Sterile filters     (Millipore, Cork, Ireland) 
30-gauge insulin syringe   (BD micro-fine, Heidelberg, Germany). 
Syringes, Omnifix-H, 1ml   (Braun, Melsungen, Germany)  
Ultracentrifuge    (Beckman Coulter, Krefeld, Germany)  
UV-cuvettes 8.5mm    (Plastiband, Antwerp, Belgium)  
Vortex     (Labnet Abimed, Langenfeld, Germany)  
Waterbath     (Labortechnik, Seelbach, Germany)  
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Kits  
  
Albumin determination kit   (microfluoral, Progen, Heidelberg, Germany)  
Aldosterone kit    (Demeditec, Kiel, Germany) 
ADH RIA kit     (Immunotech, Marseille, France; IBL, Hamburg, 
 Germany) 
Corticosterone ELISA kit   (DRG Instruments, Marburg, Germany) 
 
Creatinine determination kit   (Lehmann, Berlin, Germany) 
for Plasma - creatinine PAP  
 
Creatinine kit    (Labor technik,Berlin,Germany) 
for urine – Jaffe Kreatinin 
 
Gamma-B    (IDS, Boldon, UK)  
1.25-Dihydroxy-vitamin D 
 
Glucose kit: gluco-quant   (Roche Diagnostics, Mannheim, Germany)  
Inorganic Phosphate    (Roche Diagnostics, Mannheim, Germany)  
Insulin ELISA kit    (Mercodia, Uppsala, Sweden) 
Intact parathormone ELISA kit  (Immunotopics, San Clemente, CA, USA)  
Mouse intact PTH Elisa kit   (Immunotopics, California, USA)  
Plasma leptin ELISA kit   (Linco, St. Charles, USA)  
Urea determination kit   (Lehman,Germany) 
 
Chemicals  
  
Aqua ad injectabili    (Ampuwa, Niefern, Germany)  
Calcium chloride    (Sigma-Aldirch, Hannover,Germany) 
Dexamethasone phosphate   (Sigma, Taufkirchen, Germany) 
disodium salt 
Diethylether     (Carl Roth, Karlsruhe, Germany)  
DOCA pellets    (50 mg, Innovative Research of America, Sarasota, 
 Florida, USA)  
Ethanol absolute (99%)   (Carl Roth, Karlsruhe, Germany)  
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Evans Blue     (Sigma, Taufkirchen, Germany) 
Flumazenil     (Roche, Mannheim, Germany)  
HEPES     (Sigma, Taufkirchen, Germany)  
Ketamine     (Sigma-Aldrich, Hannover, Germany)  
Magnesiumchloride    (Sigma-Aldrich; Hannover, Germany) 
Methanol absolute (99%)   (Carl Roth, Karlsruhe, Germany)  
Midazolam     (Sigma, Taufkirchen, Germany)  
Mouse albumin standard   (Sigma, Taufkirchen, Germany)  
Natriumchloride    (Sigma-Aldrich, Hannover, Germany) 
Nitric acid(HNO3)-   (Sigma, Taufkirchen, Germany)  
Nitrogen liquide    (Linde, Wiesbaden, Germany)  
Normal saline 0.9%    (Fresenius Kabi Bad Homburg, Germany). 
Phosphate-buffered saline   (PBS tablets, Invitrogen, Karslruhe, Germany). 
Potassium chloride    (Carl Roth, Karlsruhe, Germany )  
Sterilium     (Carl Roth, Karlsruhe, Germany)  
 
Diets (Altromin, Heidenau, Germany)  
  
Standard diet C1310/1314 [0.24% Na+, 0.71% K+, 0.95% Ca2+  (wt/wt)] 
Control diet C1000 [0.24% Na+, 0.71% K+, 0.95% Ca2+ (wt/wt)]   
Low-salt diet C1036 [0.015% Na+, 0.71% K+, 0.95% Ca2+ (wt/wt)]   
 
Software   
  
Blood pressure   (PowerLab 400 and Chart 4, Colorado Springs, Colorado 
computerized data acquisition  Springs, USA)  
 
Chart version.4.2   (Axon Instruments ,USA ) 
Data link version 1.0.0   (Herbert &Scheneider Software &CAM, Siglingen, 
 Germany)  
GraphPad Instat version 3.05  (GraphPad Software Inc., San Diego, USA)  
Inveon Research Workplace   (Siemens, Germany) 
Magellan version 3.11   (Tecan GmbH, Crailsheim, Germany)  
Sigma plot version 7.0   (Systat Software Inc., Erkrath, Germany) 
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Animals 
 
All animal experiments were conducted according to the guidelines of the American 
Physiological Society and the German law for the care and welfare of animals and were 
approved by local authorities. 
 
gsk3KI mice were kindly provided by Dario Alessi which were bred homozygously. 
The mice (6 males, age 16 weeks) were fed a control diet (C1000, Altromin), 4 days a low salt 
diet (C1036, Altromin) or 4 days a high salt diet (1% NaCl solution in drinking water), as 
indicated. The mice had free access to tap drinking water and/or 1% saline as indicated. 
 
 
Mice with mutated APC (apcMin/+) and their wild type littermates (apc+/+) with a 
mixed (C57/Bl-6-Sv129J) background were generated by breeding of male apcMin/+ mice 
initially obtained from the Jackson Laboratory. Where indicated, additional mice were 
generated by crossbreeding apcMin/+ with gene targeted mice lacking functional SGK1 (sgk1-/-) 
to generate mice carrying the mutant APC and simultaneously lacking SGK1     
(apcMin/+/sgk1-/-). Sex and age matched mice of 3 months age were used for the experiments. 
 
Generation and basic properties of the SGK3 knockout mice (sgk3KO) were described 
previously 106. The mice were compared to their wild type littermates (sgk3WT) and genotyped 
by PCR on tail DNA using SGK3 and neo-R-specific primers as previously described 106. The 
mice (n = 10-13 in each group, age 3 months) were fed a control diet (C1314, Altromin, Lage, 
Germany) with free access to tap drinking water. 
 
. 
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METHODS 
 
Collection of urine and feces 
 
For evaluation of the renal and fecal excretion as well as daily food and fluid intake, mice 
were placed individually in metabolic cages for 24-hour urine and feces collection with free 
access to fluid and food. They were allowed a 3-day habituation period when food & water 
intake, urinary flow, urinary excretion of salt, fecal excretion and body weight were recorded 
every day to ascertain that the mice were adapted to the new environment. Subsequently 24h 
collection of urine was performed for three consecutive days in order to obtain the urinary 
parameters. To assure quantitative urine collection, metabolic cages were siliconized and 
urine was collected under water-saturated oil. 
 
Preparation of feces 
 
To prepare feces for the analysis of the electrolyte content, feces samples were dried at 80◦C 
for about 3 hours and weighed. After addition of 5 ml of 0.75 M HNO3 to the feces, samples 
were electrically shaken for 48 hours to yield a homogenous creamy mass. The mass was 
centrifuged at 3000 g for 10 minutes, 1 ml of the supernatant was centrifuged a second time at 
10000 g for 5 minutes, and the resulting second supernatant was used for further analysis. 
Measured electrolyte concentrations were multiplied with 5 to obtain excreted amount per day 
(in µmol/24h). 
 
Determination of plasma, urinary and fecal concentrations  
 
To obtain blood specimens, animals were lightly anesthetized with diethylether and 
approximately 130 µl of blood was withdrawn into heparinized capillaries by puncturing the 
retro-orbital plexus. Blood losses were replaced with 400 µl of 0.9 % NaCl subcutaneously. 
 
 Plasma, urinary and fecal concentrations of Na+, K+ and Ca2+ were measured by flame 
photometry. Plasma and urinary creatinine concentrations were measured using an enzymatic 
colorimetric method (Creatinine PAP). Urinary creatinine concentrations were measured 
using the Jaffe method. Plasma, urinary and fecal phosphate were measured photometrically 
using kits from Roche Diagnostics. Plasma and urinary calcium and plasma phosphate 
concentrations in SGK3 were determined by a photometric method according to the 
manufacturer’s instructions (dri-chem clinical chemistry analyzer FUJI FDC 3500i). 
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Urinary and plasma aldosterone concentrations were determined by using a 
commercial RIA kit (Demeditec), plasma and urine corticosterone concentrations were 
determined using an ELISA kit (DRG Instruments). Plasma concentrations of insulin were 
determined using an enzyme immunoassay kit (Mercodia). To estimate ADH release, the 
urinary ADH excretion has been determined as a surrogate for the plasma ADH 
concentration. Direct determination of plasma ADH concentration would require large 
volume, which could not be obtained by decapitation of the mice. Urinary ADH 
concentrations were determined by radioimmunoassay (Immunotech). In view of the circadian 
rhythm of hormone release, plasma corticosterone levels were determined prior to the 
beginning of the dark cycle at 5 p.m 
 
  Plasma intact parathormone concentrations were measured using an ELISA-kit 
(Immunotopics). Radioimmunoassay kits were employed to determine the concentrations of 
plasma 1,25(OH)-vitamin D3 (IDS). Plasma leptin levels were determined using an ELISA kit 
(Linco). All measurements were done according to the manufacturer’s instructions. 
 
Blood pressure 
 
Systolic arterial blood pressure was determined by the tail-cuff method (IITC, Model 179) at 
baseline and after respective treatments. The tail-cuff approach to determine arterial blood 
pressure requires certain precautions to reduce the stress of the animals, including appropriate 
training of the mice over multiple days and adequate pre-warming to dilate the tail artery. The 
animals were placed in a heated chamber at an ambient temperature of 28-30 °C for 15 min 
and from each animal 10-20 blood pressure traces were recorded in one session. The readings 
from 3 days were then averaged to obtain a mean blood pressure under the respective 
treatment. All recordings and data analysis were done using a computerized data acquisition 
system and software (PowerLab 400 and Chart 4, both Ad Instruments, Colorado, USA). All 
measurements were done by one person during a defined time (between 2-4 p.m). 
 
Mineralocorticoid Treatment  
 
To induce mineralocorticoid excess, gsk3KI and gsk3WT mice (8 months old, n = 6 each) were 
implanted with 21-day-release 50 mg DOCA pellet (Innovative Research of America) in the 
neck area during superficial general anesthesia (intraperitoneal midazolam 5 mg/kg + ketamin 
50 mg/kg), which was partially antagonized by flumazenil (0.5 mg/kg i.p.) afterwards. Prior 
to the pellet implantation (control period) the mice had free access to plain tap water. After 
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the implantation, the tap water was replaced by 1% NaCl (high salt). Throughout the entire 
study, mice had free access to a standard mouse diet (C1310, Altromin). Renal excretion was 
determined before and after 18 days of DOCA+1%NaCl treatment. 
 
 For analysis of dexamethasone (DEXA) effects, gsk3KI and gsk3WT mice were injected 
with dexamethasone phosphate disodium salt dissolved in 0.9% saline at a concentration of 1 
mg/ml) at a dosage of 10 µg/g body weight (BW) for four consecutive days at 5 p.m. Mice 
had free access to a standard mouse diet (C1310, Altromin) and tap water. Renal excretion 
was evaluated before and after 4 days of dexamethasone treatment. 
 
Determination of plasma volume 
 
Plasma volume was assessed by dye dilution using Evans Blue. Mice were anesthetized with 
diethylether and 30-50 µl of an Evans Blue stock solution (3 mg/ml in 0.9% NaCl) was 
injected intravenously into the left retroorbital plexus using a 30-gauge insulin syringe (BD 
micro-fine). The exact applied volume was determined by weighing the syringe before and 
after injection. Blood samples (20-25 µl) were drawn from the right retroorbital plexus during 
superficial diethylether anesthesia after 10, 30, 60 and 120 mins which each time yielded a 
volume of 10 µl plasma after centrifugation. Absorbance was measured at 620 nm against 
blank mouse serum after recovery in 90 µl phosphate-buffered saline. Plasma concentrations 
of Evans Blue were calculated using the stock solution dissolved in mouse serum as a 
standard. Division of the applied dose of Evans Blue (in mg) by the y-intercept (in mg/ml) 
resulted in the distribution volume of Evans Blue which was normalized for body weight. 
 
Determination of Bone Density  
 
For the analysis of bone density, animals were sacrificed and legs were amputated and fixated 
in formalin. The samples were scanned with a high resolution microCAT-II (Siemens, 
Germany) small animal computed tomography (CT) scanner using a field of view of  3.1 x 3.1 
x 4.8 cm³. The X-ray tube parameters were set at 80kVp and 400 µA. The images were 
acquired with 720 angular projections (exposure time 1200 ms per projection) over 360° and 
binned with a factor of two, yielding a spatial resolution of ~38 µm. The total scan time was 
24 minutes. Reconstructed CT images were analyzed with the Inveon Research Workplace 
software (Siemens, Germany) by drawing a standard-sized container around the femur and 
applying a region growth routine to segment the trabecular bone structure. For all samples, the 
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same upper and lower density threshold were applied and compared the relative numbers of 
trabecular bone density.      
 
In vitro experiments in SGK3 
 
For generation of cRNA, constructs were used encoding wild type NaPiIIa 139 and SGK3 88 
The cRNA was generated as described previously 98. SGK3 cDNA was kindly provided by Sir 
Philip Cohen, the cDNA encoding NaPiIIa by Heini Murer. For electrophysiology, Xenopus 
oocytes were prepared as previously described 140;141. 7.5 ng of wild type SGK3 and 15 ng of 
NaPiIIa cRNA were injected (one day) after preparation of Xenopus oocytes. All experiments 
were performed at room temperature 4-5 days after injection. Two electrode voltage-clamp 
recordings were performed at a holding potential of -50 mV. The data were filtered at 10 Hz, 
and recorded with Digidata A/D-D/A converter and Chart V.4.2 software for data acquisition 
and analysis (Axon Instruments). The control solution (superfusate / ND96) contained 96 mM 
NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES, pH 7.4. 3 mM phosphate 
was added to induce NaPiIIa dependent currents. The flow rate of the superfusion was 20 
ml/min and a complete exchange of the bath solution was reached within about 10 s. 
 
Data are provided as means ± SEM, n represents the number of oocytes investigated. 
All experiments were repeated with at least 3 batches of oocytes; in all repetitions 
qualitatively similar data were obtained. Data were tested for significance using ANOVA and 
results with p < 0.05 were considered statistically significant 
 
Statistical analysis 
 
Data are provided as means ± SEM, n represents the number of independent experiments.. All 
data were tested for significance using paired or unpaired Student t-test or ANOVA where 
ever applicable and only results with p < 0.05 were considered statistically significant. 
GraphPad InStat version 3.00 for Windows 95 (GraphPad Software, San Diego, USA) was 
used. 
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RESULTS 
 
The role of PKB/SGK resistant GSK3 in renal water and electrolyte 
excretion as well as steroid hormone release 
 
Food (Figure 6A) and water (Figure 6B) intakes were slightly but significantly larger in 
gsk3KI than in gsk3WT mice. In parallel to the enhanced food intake, fecal excretion was again 
significantly larger in gsk3KI than in gsk3WT mice (Figure 6C). Despite the increased food and 
water intake, body weight was similar in gsk3KI and in gsk3WT mice (Figure 6D).  
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Figure 6: Food and fluid intake, fecal excretion, body weight and packed cell volume in gsk3KI and gsk3WT 
mice on standard diet, low salt and high-salt intake.  
Arithmetic means ± SEM (n=6 each group) of food intake (A), fluid intake (B), fecal excretion (C), body weight 
(D) and packed cell volume (hematocrit, (E) in GSK3 knockin mice (gsk3KI, closed bars) and their wild-type 
littermates (gsk3WT, open bars) under standard diet (SD), under low-salt diet (Low salt) and under high-salt diet 
(High salt). # p < 0.05 vs respective value under SD,* p < 0.05 vs respective value of gsk3WT mice. 
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 Packed cell volume (hematocrit) tended to be higher in gsk3KI than in gsk3WT mice, a 
difference, however, not reaching statistical significance (Figure 6E). Further experiments 
were performed to explore the food and fluid intake in normal cages. Food (211.2 ± 8.7 
mg/24h/g bw, n = 8 vs 149.6 ± 7.42 µg/24h/g bw) and fluid inake (311.4 ± 19.5 µl /24h/g bw, 
n = 8 vs 192.8 ± 12.4 µl /24h/g bw) were significantly larger in gsk3KI than in gsk3WT mice. 
  
 Plasma insulin concentrations were similar in gsk3KI mice (0.5 ± 0.1 ng/ml) and in 
gsk3WT mice (0.4 ± 0.1 ng/ml). In contrast, plasma corticosterone concentrations were 
significantly lower in gsk3KI mice than in gsk3WT mice (Figure 7B). Moreover, aldosterone 
concentration was significantly lower in gsk3KI than in gsk3WT mice (Figure. 7A). Low salt 
diet increased and high salt diet tended to decrease plasma aldosterone levels. Neither diet 
abrogated the difference between the genotypes (Figure 7A). In contrast to plasma hormone 
concentrations, the urinary excretion of aldosterone was significantly higher and 
corticosterone excretion tended to be higher in gsk3KI than in gsk3WT mice. Urinary excretion 
of vasopressin (ADH) was similar in gsk3KI and gsk3WT mice during control diet and low salt 
diet but increased to significantly higher levels d
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Figure 7: Plasma aldosterone and corticosterone concentrations and urinary vasopressin excretion in 
gsk3KI and gsk3WT mice on standard diet, low-salt and high-salt intake.  
Arithmetic means ± SEM (n=6 each group) of aldosterone plasma concentrations (A), Corticosterone 
concentrations (B) and urinary vasopressin excretion (C) in GSK3 knockin mice (gsk3KI, closed bars) and their 
wild-type littermates (gsk3WT , open bars) under standard diet (SD), under low-salt diet (Low salt) and under 
high-salt diet (High salt). # p < 0.05 vs respective value under SD,* p < 0.05 vs respective value of gsk3WT mice. 
 
 
 Plasma Na+ concentration was slightly but significantly lower in gsk3KI than in gsk3WT 
mice under control diet (Figure 8A). Low salt diet significantly decreased plasma Na+ 
concentration in gsk3WT mice but not in gsk3KI mice and thus dissipated the difference 
between gsk3KI and gsk3WT mice. High salt diet was followed by a significant increase of 
plasma Na+ concentration in both, gsk3KI and gsk3WT mice, and again dissipated the difference 
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between genotypes (Figure 8A). Plasma K+ concentration was similar in gsk3KI and gsk3WT 
mice under control, low and high salt diet (Figure 8B). 
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Figure 8: Plasma Na+ and K+ concentrations in gsk3KI and gsk3WT mice on standard diet, low-salt and 
high-salt intake. 
Arithmetic means ± SEM (n=6 each group) of plasma Na+ (A) and K+ (B) concentrations in GSK3 knockin mice 
(gsk3KI, closed bars) and their wild-type littermates (gsk3WT, open bars) under standard diet (SD), under low salt 
diet (Low salt) and under high-salt diet (High salt). # p < 0.05 vs respective value under SD,* p < 0.05 vs 
respective value of gsk3WT mice. 
 
 
 Urinary flow rate was significantly larger in gsk3KI than in gsk3WT mice, an effect 
persisting under both, low and high salt diet (Figure 9A). Urinary Na+ excretion was similarly 
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larger in gsk3KI than in gsk3WT mice. Low salt diet significantly decreased urinary Na+ output 
to similarly low levels in both genotypes (Figure 9B). High salt diet significantly increased 
renal Na+ excretion in both genotypes. Urinary Na+ excretion remained, however, 
significantly larger in gsk3KI than in gsk3WT mice during high salt diet (Figure 9B). Under 
control diet, urinary K+ excretion was again significantly higher in gsk3KI than in gsk3WT mice 
(Figure 9C). The difference was, however, dissipated by low and high salt diet (Figure 9C). 
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Figure 9: Urinary flow rate and urinary excretion of Na+ and K+ in gsk3KI and gsk3WT mice on standard 
diet, low-salt and high-salt intake.  
Arithmetic means ± SEM (n=6 each group) of urinary flow rate (A), and urinary excretion of Na+ (B), and K+ 
(C) in GSK3 knockin mice (gsk3KI, closed bars) and their wild-type littermates (gsk3WT, open bars) under 
standard diet (SD), under low-salt diet (Low salt) and under high-salt diet (High salt).  #p<0.05 vs respective 
value under SD, *p<0.05 vs respective value of gsk3WT mice. 
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 Under control diet the creatinine clearance as well as urinary urea, creatinine, glucose 
and aldosterone excretions were significantly larger in gsk3KI mice than in gsk3WT mice (Table 
1). Plasma creatinine and urea concentrations were slightly but significantly lower in gsk3KI 
than in gsk3WT mice under control diet (Table 1). Plasma glucose concentration was not 
significantly different between gsk3KI and gsk3WT mice (Table 1). 
 
 As shown in Figure 10, urine osmolarity was significantly higher in gsk3KI than in 
gsk3WT mice. Water deprivation further increased urine osmolarity, an effect, reaching 
statistical significance only in gsk3KI mice (Figure 10B). Plasma osmolarity was not 
significantly different between gsk3KI and gsk3WT mice and was not significantly altered by 
water deprivation (Figure 10C). Body weight decreased during water deprivation (Figure 
10E), an effect significantly larger in gsk3KI mice (Figure 10D). 
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Figure 10: Urinary flow rate, plasma and urinary osmolarity as well as body weight in gsk3KI and gsk3WT 
mice on standard diet before and after water deprivation. Arithmetic means ± SEM (n=6 each group) of 
urinary flow rate (A), urinary (B), and plasma (C) osmolarity, change of (∆) body weight (D) as well as body 
weight (E) in GSK3 knockin mice (gsk3KI, closed bars) and their wild-type littermates (gsk3WT, open bars). # p < 
0.05 vs respective value under SD, * p < 0.05 vs respective value of gsk3WT mice. 
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 Additional experiments were performed to elucidate, whether the decreased 
aldosterone levels in gsk3KI mice resulted in a reduced salt appetite. To this end, the mice 
were offered two drinking bottles, one containing plain tap water and the other 1 % saline. As 
illustrated in Figure 11, the gsk3WT mice significantly preferred saline. The gsk3KI mice drank 
similar volumes of saline but larger volumes of tap water than gsk3WT mice. As a result, 
gsk3KI mice drank similar volumes of saline and tap water (Figure 11). 
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Figure 11: Fluid intake from tap water or saline by gsk3KI and gsk3WT mice. 
Arithmetic means ± SEM (n=6 each group) of volumes tap water intake (water) or 1% saline (1% NaCl) drunk 
per day (upper panel)as well as the preference of saline, i.e., the ratio of saline/water drunk (lower panel) by 
GSK3 knockin mice (gsk3KI, closed bars) and their wild-type littermates (gsk3WT, open bars). * p < 0.05 vs 
respective value of gsk3WT mice. 
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 Systolic blood pressure was slightly but significantly higher in gsk3KI than in gsk3WT 
mice during control diet and during low salt diet (Figure 12), a difference abrogated by high 
salt diet. Low salt diet significantly decreased the blood pressure in gsk3WT mice. To test, 
whether the difference between gsk3KI and gsk3WT mice was due to differences in circadian 
rhythm, systolic blood pressure was measured at both, 1 p.m and 10 p.m. Systolic blood 
pressure was significantly higher in gsk3KI than in gsk3WT mice at both, 1 p.m. (101.26 ± 1.8 
vs 90.3 ± 1.8 mmHg) and 10 p.m. (102.46 ± 2.6 vs 89.4 ± 1.2 mmHg, n=6-7).   
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Figure 12: Systolic blood pressure in gsk3KI and gsk3WT mice on standard diet, low-salt and high-salt 
intake.  
Arithmetic means±SEM (n=6 each group) of systolic blood pressure (BP) in GSK3 knockin mice (gsk3KI, closed 
bars) and their wild-type littermates (gsk3WT, open bars) under standard diet (SD), under low-salt diet (Low salt) 
and under high salt diet (High salt). # p < 0.05 vs respective value under SD, * p < 0.05 vs respective value of 
gsk3WT mice. 
 
 
 Body temperature was significantly higher in gsk3KI mice (38.8 ± 0.2 0C, n = 9) than in 
gsk3WT mice (36.8 ± 0.2 ◦C, n = 9).   
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 Further experiments were performed to explore urinary Na+ and K+ excretion during 
mineralocorticoid or glucocorticoid excess. Prior to hormone application urinary Na+ and K+ 
excretion was significantly higher in gsk3KI than in gsk3WT mice. Following treatment with 
DEXA (Figure 13B) or DOCA (Figure 14B) the urinary Na+ excretion was still significantly 
higher in gsk3KI than in gsk3WT mice. Urinary K+ excretion, however, was not significantly 
different between the genotypes after the DEXA or DOCA treatment (Figure 13C and Figure 
14C). 
 
0
2
4
6
8
SD DEXA
Ur
in
ar
y
N
a+
ex
cr
et
io
n
(µm
o
l/2
4h
/g
 
B
W
)
*
#
*,#
0
5
10
15
20
25
30
SD DEXA 
Ur
in
ar
y
K
+
ex
cr
et
io
n
(µm
o
l/2
4h
/g
 
bw
*
#
#
0
15
30
45
60
75
90
105
SD DEXA 
Ur
in
ar
y
flo
w
ra
te
(µl
/2
4h
 
g 
B
W
)
*
#
A)
B)
C)
gsk3WT (n=6)
gsk3KI (n=6)
Ur
in
ar
y
N
a+
ex
cr
et
io
n
(µm
o
l/2
4h
/g
 
B
W
)
Ur
in
ar
y
N
a+
ex
cr
et
io
n
(µm
o
l/2
4h
/g
 
B
W
)
Ur
in
ar
y
K
+
ex
cr
et
io
n
(µm
o
l/2
4h
/g
 
bw
Ur
in
ar
y
K
+
ex
cr
et
io
n
(µm
o
l/2
4h
/g
 
bw
Ur
in
ar
y
flo
w
ra
te
(µl
/2
4h
 
g 
B
W
)
Ur
in
ar
y
flo
w
ra
te
(µl
/2
4h
 
g 
B
W
)
Ur
in
ar
y
flo
w
ra
te
(µl
/2
4h
 
g 
B
W
)
 
 
Figure 13: Urinary flow rate and urinary excretion of Na+ and K+ in gsk3KI and gsk3WT mice before and 
after DEXA treatment.  
Arithmetic means ± SEM (n=6 each group) of urinary flow rate (A) and urinary excretion of Na+ (B) and K+ (C) 
in GSK3 knockin mice (gsk3KI, closed bars) and their wild-type littermates (gsk3WT, open bars) before (left 
panels) and after (right panels) 4-days DEXA treatment. # p < 0.05 vs respective value under SD, * p < 0.05 vs 
respective value of gsk3WT mice. 
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Figure 14: Urinary flow rate and urinary excretion of Na+ and K+ in gsk3KI and gsk3WT mice before and 
after DOCA treatment.  
Arithmetic means ± SEM (n=5–6 each group) of urinary flow rate (A) and urinary excretion of Na+ (B) and K+ 
(C) in GSK3 knockin mice (gsk3KI, closed bars) and their wild-type littermates (gsk3WT, open bars) before (left 
panels) and after (right panels) an 18-day DOCA + 1% NaCl treatment. # p < 0.05 vs respective value under SD, 
* p < 0.05 vs respective value of gsk3WT mice. 
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Table 1: Effect of standard diet, low salt and high salt diet on plasma concentrations and urinary 
excretion of electrolytes and hormones. 
Creatinine, urea concentrations in plasma, renal excretions of glucose, urea, creatinine clearance, aldosterone, 
corticosterone and fractional renal excretions of Na+ and K+ in both  gsk3KI and in gsk3WT mice. 
 
Standard diet 
 (n=6) 
Low salt diet  
(n=6) 
High salt diet 
(n=6) 
 
gsk3WT gsk3KI gsk3WT gsk3KI gsk3WT gsk3KI 
[Creatinine]plasma (mg/dl) 0.13 ± 0.01 0.09 ± 0.01* 0.18 ± 0.03 0.21 ± 0.02# 0.30 ± 0.05# 0.25 ± 0.05 
[Urea]plasma (mg/dl) 54.9±2 47.0±2* 47.2±5 45.6±3 51.5±3 44.0±2* 
[Glucose]
 plasma (mg/dl) 137.6±6.7 126.6±9.0 ND ND ND ND 
Urinary creatinine  
(µg/24h/g BW) 
13.9±1.2 17.0±0.7* 22.6±1.5# 22.4±1.1# 16.5±1.3 16.5±1.3 
Creatinine clearance  
(µl/min/g BW) 
7.4±0.6 14.4±1.7* 9.9±1.7 8.0±0.8# 4.3±0.7# 4.9±1.3# 
Urine urea (mg/24h) 150.2±14 207.2±11* 161.5±11 174.6±7.3# 189.2±21 226.1±15 
Urine glucose (mg/24h) 0.4±0.05 1.7±0.5* 0.5±0.1 1.8±0.3 0.5±0.04 0.86±0.04 
FE Na+ (%) 0.49±0.06 0.42±0.07 0.04±0.01# 0.04±0.01# 3.14±0.48# 4.02±0.81’# 
FE K+ (%) 30.6±3.38 21.8±2.35 17.0±1.95 14.3±2.37 54.9±6.16# 59.7±13.27# 
Urine aldosterone  
(ng/24h) 
8.3±0.8 12.7±1.1* 19.7±4.8# 22.1±4.1 7.4±0.7 10.8±1.1 
Urine corticosterone 
(nmol/24h) 
0.11±0.02 0.23±0.07 0.20 ± 0.03# 0.42±0.14# 0.15±0.02# 0.29±0.11 
 
Arithmetic means ± SEM; # p<0.05 vs. respective value under SD, * p<0.05 vs. respective value of gsk3WT mice, 
ND- Not determined. 
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SGK1 dependence of renal electrolyte balance and hormone 
regulation in APC min mice 
 
The body weight was similar in apcMin/+ mice, apc+/+ mice and apcMin/+/sgk1-/- mice (Table 2). 
Similarly, food intake and fluid intake were not significantly different between the genotypes. 
Urine flow tended to be lower in apcMin/+ mice than in apc+/+ mice and apcMin/+/sgk1-/- mice, a 
difference, however, not reaching statistical significance. Mean fractional urinary excretion of 
K+ was significantly higher in apcMin/+ and apcMin/+/sgk1-/- mice than in apc+/+ mice. In 
contrast, absolute urinary excretion of Na+ was significantly lower in apcMin/+ mice than in 
apc+/+ mice. The absolute Na+ excretion tended to be higher in apcMin/+/sgk1-/- mice than in 
apcMin/+ mice and was not significantly different from the respective value in apc+/+ mice 
(Table 2). Thus, lack of SGK1 appeared to abrogate the decrease of renal Na+ excretion in 
mice carrying the mutant APC.  
 
 Fecal excretion was studied to further clarify the electrolyte homeostasis and as shown 
in Table 2, feacal dry weight was not different between the genotypes. Fecal sodium and 
potassium excretion was significantly higher in apcMin/+ mice than in apc+/+ mice. The 
additional lack of SGK1 could reverse the difference in fecal sodium excretion but did not 
reverse the increase of fecal potassium excretion (Table 2).  
 
 Serum creatinine concentration was significantly higher in apcMin/+ mice than in apc+/+ 
mice, a difference, which was abrogated by additional lack of SGK1 (apcMin/+/sgk1-/- mice). 
The glomerular filtration rate was also significantly lower in apcMin/+ mice and the additional 
lack of SGK1 tended to partially reverse the difference (Table 2). 
 
 Plasma corticosterone and aldosterone concentrations were significantly higher in 
apcMin/+ mice than in apc+/+ mice (Figure 15). While plasma corticosterone concentration was 
similar in apc+/+ mice and apcMin/+/sgk1-/- mice, plasma aldosterone was even higher in 
apcMin/+/sgk1-/- mice than in apcMin/+ mice (Figure 15). 
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Figure 15: Plasma aldosterone and corticosterone concentrations in apcMin/+ mice, apc+/+ mice and 
apcMin/+/sgk1-/- mice 
Arithmetic means ± SEM of plasma aldosterone concentrations(n = 7-9) (A) and corticosterone concentrations (n 
= 11-13 ) (B) in mice carrying a defective APC (apcMin/+, black bar), their wild type littermates (apc+/+, white 
bar) and mice with defective APC and in addition lacking SGK1 (apcMin/+/sgk1-/-, grey bar). * indicates 
statistically significant (p<0.05) difference between apc+/+ and apcMin/+ mice. # indicates statistically significant 
(p<0.05) difference between apcMin/+ and apcMin/+/sgk1-/- mice. § indicates statistically significant (p<0.05) 
difference between apc+/+ and apcMin/+/sgk1-/- mice. 
 
 
 To test whether enhanced corticosterone and aldosterone concentrations were the 
result of volume depletion, plasma volume was determined utilizing Evans blue distribution. 
As illustrated in Figure 16, plasma volume was significantly higher in apcMin/+ mice than in 
apc+/+ mice, a difference partially reversed by additional lack of SGK1 (apcMin/+/sgk1-/- mice). 
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Figure 16: Plasma volume in apcMin/+mice, apc+/+mice and apcMin/+/sgk1-/- mice 
A. Representative experiment demonstrating the time-dependent decay of Evans Blue plasma concentration. 
B. Arithmetic means ± SEM (n = 8-14 ) of relative plasma volume (per gram body weight) of mice carrying a 
defective APC (apcMin/+, black bar), their wild type littermates (apc+/+, white bar) and mice with defective APC 
and in addition lacking SGK1 (apcMin/+/sgk1-/-, grey bar). Plasma volume has been determined utilizing Evans 
Blue.* indicates statistically significant (p<0.05) difference between apc+/+ and apcMin/+ mice. 
 
 
 As body weight was similar in the three genotypes despite the differences in plasma 
volume, the increased extracellular volume of APC deficient mice may have been paralleled 
by a decrease of body fat. Thus, serum leptin concentrations were measured in order to depict 
differences in body fat. Serum leptin concentrations were significantly lower in both apcMin/+ 
and apcMin/+/sgk1-/- mice than in apc+/+ mice (Table 2). Thus, APC deficiency decreased the 
body fat, an effect not sensitive to additional lack of SGK1. 
 
 Additional experiments were performed to elucidate whether the altered renal Na+ 
output was paralleled by enhanced salt appetite. To this end, animals were offered two bottles, 
one with tap water and the other with saline. As shown in Figure 17, neither apcMin/+ mice nor 
apc+/+ mice preferred water or saline and there were no differences in salt appetite between 
the two genotypes.  
 
Results                                                                                                                               VIII 
 50 
0
2
4
6
8
Water 1% NaCl
M
e
a
n
Sa
lt/
W
a
te
r
in
ta
ke
(m
l)
0.0
0.6
1.2
1.8
2.4
Ra
tio
 
o
f f
lu
id
in
ta
ke
(sa
lt/
w
a
te
r)
apc+/+
apcMin/+
M
e
a
n
Sa
lt/
W
a
te
r
in
ta
ke
(m
l)
Ra
tio
 
o
f f
lu
id
in
ta
ke
(sa
lt/
w
a
te
r)
 
 
Figure 17: Plain tap water and saline consumption of in apcMin/+ mice and apc+/+ mice 
Arithmetic means ± SEM (n = 12 each group) of daily drinking volumes of plain tap water (water) and 1% saline 
(NaCl) in mice carrying a defective APC (apcMin/+, black bar) and their wild type littermates (apc+/+, white bar). 
 
 Hyperaldosteronism is known to elevate blood pressure. Thus, blood pressure was 
determined in an additional series of experiments. As illustrated in Figure 18, blood pressure 
was indeed significantly higher in apcMin/+ mice than in apc+/+ mice. The difference was 
partially reversed by additional lack of SGK1 (apcMin/+/sgk1-/-).  
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Figure 18: Systolic blood pressure in apcMin/+ mice, apc+/+ mice and apcMin/+/sgk1-/- mice 
Arithmetic means ± SEM of systolic blood pressure (BP) in mice carrying a defective APC (apcMin/+, n = 7, 
black bar), their wild type littermates (apc+/+, n = 6, white bar) and mice with defective APC and in addition 
lacking SGK1 (apcMin/+/sgk1-/-, n = 5, grey bar). * indicates statistically significant (p<0.05) difference between 
apc+/+ and apcMin/+ mice. # indicates statistically significant (p<0.05) difference between apcMin/+and 
apcMin/+/sgk1-/- mice. 
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Table 2: Body weight, food and fluid intake, urinary flow, fecal dry weight, creatinine clearance, absolute 
and fractional urinary Na+, K+ excretion, plasma and fecal Na+, K+ concentrations and plasma leptin 
concentration in apc+/+ mice, apcMin/+ mice and apcMin/+/sgk1-/- mice (n = 13-16, except leptin [n = 6]). 
 
 apc+/+ apcMin/+ apcMin/+/sgk1-/- 
Body weight (g) 25.6 ± 1.0 25.0 ± 0.9 24.3 ± 0.7 
Food intake (mg/24h) 4.0 ± 0.2 3.9 ± 0.2 3.8 ± 0.2 
Fluid intake (ml/24h) 6.1 ± 0.4 5.5 ± 0.2 5.5 ± 0.3 
Urinary flow (µl/24h/g BW) 38.9 ± 3.9 28.2 ± 4.7 34.2 ± 4.3 
Fecal Dry Weight (mg/24h/g BW) 48 ± 5 54 ± 3 52 ± 3 
[Creatinine]plasma (mg/dl) 0.30 ± 0.02 0.43 ± 0.04* 0.36 ± 0.03 
Urinary creatinine (µg/24h/g BW) 27 ± 2 22 ± 2 21 ± 2 
Creatinine clearance (µl/min/g BW) 6.6 ± 0.6 4.0 ± 0.5* 4.4 ± 0.6* 
Urinary Na+ excretion (µmol/24h) 134 ± 14 79± 14* 123 ± 17 
Urinary K+ excretion (µmol/24h) 509 ± 26 431 ± 45 448 ± 50 
Plasma Na+ concentration (mM) 150 ± 2 151 ± 2 152 ± 2 
Plasma K+ concentration (mM) 3.82 ± 0.10 3.76 ± 0.09 3.73 ± 0.08 
Plasma Leptin (ng/ml)  2.38 ± 0.57 0.77 ± 0.13* 0.67 ± 0.16* 
FE Na+ (%) 0.42± 0.03 0.43 ±0.07 0.61 ± 0.06 
FE K+ (%) 66.± 6 98 ± 1* 96 ± 10* 
Fecal Na+ (µmol/24h) 148 ± 17 206 ± 14* 120 ± 108# 
Fecal K+ (µmol/24h) 229 ± 15 286 ± 20* 286 ± 19* 
 
* indicates statistically significant (p<0.05) difference with respect to apc+/+ mice.  
# indicates statistically significant (p<0.05) difference with respect to apcMin/+ mice. 
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The role of SGK3 in renal phosphate handling 
 
A first series of experiments analysed the in vitro influence of the serum and glucocorticoid-
inducible kinase isoform SGK3 on NaPiIIa, the major renal tubular phosphate transporter. 
Exposure of noninjected Xenopus oocytes to phosphate (3 mM) in the bath solution did not 
induce a significant current, indicating that those oocytes do not express significant 
endogenous electrogenic phosphate transport (Figure 19). In oocytes injected with cRNA 
encoding NaPiIIa, however, the addition of phosphate (3 mM) induced an inward current 
(Ipi). Coexpression of SGK3 significantly increased Ipi in NaPiIIa-expressing oocytes. 
Expression of SGK3 alone did not induce Ipi, indicating that SGK3 was indeed effective by 
stimulating NaPiIIa.  
 
 
 
Figure 19: Coexpression of SGK3 stimulates electrogenic phosphate transport in NaPiIIa-expressing 
Xenopus oocytes 
Arithmetic means ± SEM of phosphate (3 mM)-induced currents (IPi) in Xenopus oocytes injected with water 
(H20) or SGK3 or NaPiIIa, or SGK3 and NaPiIIa cRNA. *indicates significant difference from absence of 
NaPiIIa cRNA. ### indicates significant absence from SGK3 cRNA (p<0.001). 
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 A second series of experiments explored whether SGK3 participates in the regulation 
of renal phosphate excretion in vivo. To this end, metabolic cage experiments were performed 
in gene targeted mice lacking functional SGK3 (sgk3KO) and their wild-type littermates 
(sgk3WT). As shown in Table 3, the body weight was similar in sgk3KO mice and sgk3WT mice. 
Fluid intake tended to be slightly higher in sgk3KO than in sgk3WT mice, a difference, however, 
not reaching statistical significance (Table 3). Food intake was slightly but significantly 
higher in sgk3KO than in sgk3WT mice (Table 3). 
 
 No significant differences were observed between the genotypes in plasma Ca2+ and 
phosphate concentrations (Table 3).  
 Urinary flow rate and creatinine clearance each tended to be slightly higher in sgk3KO 
mice than in sgk3WT mice, a difference, however, not reaching statistical significance (Table 
3). Absolute (Table 3) and fractional (Figure 20) excretion of Ca2+ were not significantly 
different between the two genotypes. In contrast, absolute (Table 3) and fractional (Figure 20) 
excretion of phosphate were significantly higher in sgk3KO mice than in sgk3WT mice. Neither 
in the sgk3WT nor in the sgk3KO mice glucosuria was observed. 
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Figure 20: Fractional excretion of calcium and phosphate in sgk3KO and sgk3WT mice  
Arithmetic means ± SEM (n = 10-12 each group) of fractional urinary calcium (left panel) and phosphate (right 
panel) excretion in SGK3 knockout mice (sgk3KO, closed bars) and their wild type littermates (sgk3WT, open 
bars).* p<0.05 vs. respective value of sgk3WT mice. 
   
 
 The phosphaturia could have been secondary to increased parathyroid hormone 
release. Thus, plasma PTH levels were determined. As illustrated in Figure 21C, PTH plasma 
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concentration was not significantly different between genotypes. However, plasma 
1,25(OH)2D3 concentration was significantly lower in sgk3KO than in sgk3WT mice(Figure 
21D).  
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Figure 21: Plasma calcium, phosphate, PTH and 1,25(OH)2D3 concentrations in sgk3KO and sgk3WT mice 
Arithmetic means ± SEM of plasma calcium (A), phosphate (B) (n = 10 each group), PTH (C) and 1,25(OH)2D3 
(D) (n = 10-12 each group) concentration in SGK3 knockout mice (sgk3KO, closed bars) and their wild type 
littermates (sgk3WT, open bars).* p<0.05 vs. respective value of sgk3WT mice. 
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 Renal loss of phosphate was expected to foster demineralization of bone. Thus, bone 
density was determined in sgk3KO and sgk3WT mice. As shown in Figure 22, the bone density 
was indeed lower in sgk3KO mice than in sgk3WT mice. 
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Figure 22: Bone density of sgk3KO and sgk3WT mice 
Arithmetic means ± SEM (n = 6 each group) of bone density in SGK3 knockout mice (sgk3KO, closed bars) and 
their wild type littermates (sgk3WT, open bars).* p<0.05 vs. respective value of sgk3WT mice. 
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Table 3: Analysis of blood and urine of sgk3KO and sgk3WT mice 
Body weight, food and fluid intake, plasma concentrations and renal excretions of Ca2+ and phosphate, urinary flow 
rate, creatinine clearance and fractional renal excretions of Ca2+ and phosphate in SGK3 knockout mice (sgk3KO) 
and their wild type littermates (sgk3WT).  
 
 sgk3WT sgk3KO 
Body weight (g) 24.01±0.69 23.48±0.75 
Food intake (mg/g BW) 180.9±8.9 210.4±8.9* 
Fluid intake (mg/g BW) 299.9±16.7 318.7±16.6 
[Ca2+]plasma (mg/dl) 9.31±0.08 9.33±0.11 
[Pi]plasma (mg/dl) 6.70±0.22 7.15±0.19 
Urine Ca2+ (µmol/24h/g BW) 0.30±0.02 0.31±0.03 
Urine Pi (µmol/24h/g BW) 0.18±0.03 0.62±0.12* 
Urinary flow (µl/24h/g BW) 51.47±8.77 63.93±5.47 
Creatinine clearance (µl/min/g BW) 4.78±0.55 6.05±0.95 
Fractional excretion of Ca2+ (%) 1.92±0.19 1.79±0.13 
Fractional excretion of Pi (%) 1.50±0.42 3.20±0.69* 
 
Arithmetic means ± SEM (n = 10 - 13); * indicates significant difference between genotypes (p<0.05). 
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DISCUSSION 
 
The role of PKB/SGK resistant GSK3 in renal water and electrolyte 
excretion as well as steroid hormone release 
 
The present study reveals several subtle differences between gsk3KI and gsk3WT mice. Food 
intake was significantly higher in gsk3KI than in gsk3WT mice even though the body weight 
was similar in both genotypes. In search for a possible explanation for this seeming 
discrepancy, we hypothesized that gsk3KI mice had enhanced metabolic turnover and thus 
determined body temperature. Rectal temperature was indeed significantly higher in gsk3KI 
than in gsk3WT mice. The elucidation of enhanced body temperature is beyond the scope of 
this study and future studies shall be directed to elucidate the underlying cause. Enhanced 
metabolic turnover is further reflected by enhanced urinary urea excretion, an indicator for 
enhanced protein degradation 142. Increased urinary urea excretion could have contributed to 
the higher urine osmolarity in gsk3KI mice 143. Notably, plasma urea concentration is rather 
lower and thus, renal urea clearance enhanced. 
  
 Enhanced food intake is paralleled by increased electrolyte intake. Enhanced renal Na+ 
excretion may at least partially be due to reduced plasma aldosterone levels. 
Hypoaldosteronism should, however, not increase but decrease urinary K+ excretion. Plasma 
K+ concentration was not different between gsk3KI and gsk3WT mice at any of the diets offered 
to the mice and differences in plasma K+ concentration cannot account for the kaliuresis of the 
gsk3KI mice. Thus, a renal mechanism presumably causes enhanced renal K+ excretion. 
Lithium, an inhibitor of GSK, downregulates distal nephron ENaC expression 144, which is 
expected to decrease distal tubular K+ secretion. Conversely, overactivity of GSK3 in gsk3KI 
mice may enhance ENaC activity, thus enhancing the driving for K+ secretion. 
 
 Fluid intake was again significantly higher in gsk3KI than in gsk3WT mice. The 
enhanced fluid intake parallels the enhanced urinary flow rate of gsk3KI mice. The enhanced 
urinary flow rate in gsk3KI mice does not reflect decreased ability of urinary concentration, as 
urinary osmolarity is increased. Moreover, water deprivation did not abrogate the differences 
in urinary output between gsk3KI and gsk3WT mice. At high salt diet, the increased urinary 
osmolarity could be explained by increased ADH excretion. Beyond that, GSK3 may 
participate in the regulation of renal tubular water transport. Along those lines lithium, an 
inhibitor of GSK3, causes nephrogenic diabetes insipidus 145. Lithium increases 
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cycloxygenase expression, leading to enhanced formation of prostaglandins and subsequent 
polyuria 145. 
 
  The increased fluid intake of gsk3KI mice was not dependent on salt intake. Moreover, 
when offered the choice between tap water and saline, the gsk3KI mice drank similar volumes 
of saline as the gsk3WT mice, but continued to drink larger volumes of tap water than their 
wild-type littermates. Accordingly, unlike the gsk3WT mice, gsk3KI mice did not drink 
significantly more saline than tap water. The enhanced fluid intake of gsk3KI mice cannot be 
explained by enhanced plasma Na+ concentration or osmolarity. Notably, inhibition of GSK3 
by lithium has been reported to upregulate eNOS 146 and inhibition of NO-synthase by L-
NAME enhances thirst following Lipopolysaccharide (LPS) injection 147. Taken together, one 
may speculate that unrestrained GSK3 could downregulate NO-synthase and that the lowering 
of NO induces thirst. Clearly, additional experimental effort is needed to determine the role of 
GSK3 in the regulation of thirst. 
 
The role of GSK3 in the regulation of eNOS 146 may further contribute to or even 
account for the differences of blood pressure between gsk3KI and gsk3WT mice. Blood pressure 
was higher in gsk3KI than in gsk3WT mice both, at 1 p.m. and 10 p.m.  
 
 In both, gsk3KI and gsk3WT mice, hematocrit increased significantly following a low 
Na+ diet. The reduced salt intake led to a decrease of plasma Na+ concentration, a difference 
reaching statistical significance in gsk3WT mice. The decreased extracellular Na+ concentration 
is expected to favour water movement from extracellular space into cells and thus increase the 
erythrocyte volume at the expense of plasma volume.  
 
Under control diet the creatinine clearance was significantly higher in gsk3KI than in 
gsk3WT mice. The present study did not attempt to define the underlying mechanisms. It is 
noteworthy, however, that GSK3ß expressed in the glomerula inactivates Snail, which in turn 
decreases the transcription of nephrin 148. Thus, GSK3ß presumably participates in the 
regulation of glomerular function.  
 
Plasma aldosterone at 10 a.m. and plasma corticosterone levels were at 5 p.m. indeed 
significantly lower in gsk3KI than in gsk3WT mice. However, the urinary excretion of 
aldosterone was significantly higher and corticosterone excretion tended to be higher in gsk3KI 
than in gsk3WT mice. The discrepancy may result from an influence of GSK on circadian 
rhythm 79;149. Moreover, according to unpublished observations, plasma protein concentration 
is decreased in gsk3KI mice. Decreased plasma protein binding could contribute to the reduced 
plasma steroid levels in those mice. 
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gsk3KI mice are devoid of SGK1-dependent regulation of GSK3. Accordingly, some 
parallel findings were expected in gsk3KI mice and in gene targeted mice lacking functional 
SGK1 (sgk1-/-). However, the properties of gsk3KI and sgk1-/- differ in a variety of aspects. As 
compared to their wild type littermates, sgk1-/- mice have enhanced plasma aldosterone levels 
and are unable to adequately decrease urinary Na+ output following exposure to salt-deficient 
diet 61. In contrast, gsk3KI have lower plasma aldosterone concentrations than gsk3WT mice and 
adequately decrease urinary Na+ excretion during salt depletion. Moreover, sgk1-/- mice are 
unable to adequately increase renal K+ excretion during acute and chronic K+ loading 62. In 
contrast, renal K+ excretion is rather enhanced in gsk3KI mice despite normal plasma K+ 
concentration. Thus, SGK1-dependent regulation of renal Na+ and K+ excretion is obviously 
not due to phosphorylation and inhibition of GSK3. Instead, SGK1 is partially effective 
through stimulation of ENaC expression 114, phosphorylation of the ENaC alpha-subunit 150 
and phosphorylation of Nedd4-2 151. Apparently, GSK3 influences renal water and electrolyte 
excretion via SGK1 independent mechanisms. 
 
In conclusion, insensitivity of GSK3 to the inhibitory action of PKB and SGK1 leads 
to a decrease of plasma corticosterone and aldosterone levels, decreased salt appetite, 
enhanced renal Na+ excretion, hyponatremia, enhanced susceptibility to water deprivation and 
increased blood pressure. The present observations disclose a completely novel element in the 
regulation of water and electrolyte metabolism.  
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 SGK1 dependence of renal electrolyte balance and hormone 
regulation in APC min mice 
 
The present observations reveal several subtle differences between mice carrying a mutation 
in the APC gene (apcMin/+) and their wild type littermates (apc+/+). Most importantly, the 
apcMin/+ mice had higher plasma aldosterone and plasma corticosterone concentrations than 
the apc+/+ mice.  
 
 Lack of APC could, at least in theory, modify electrolyte homoestasis by decreased 
degradation of ß-catenin with subsequent increase of ß-catenin levels and stimulation of 
SGK1 expression. As demonstrated earlier, genes upregulated by ß-catenin include SGK1 
125;126
, which in turn phosphorylates glycogen synthase kinase 3 (GSK3) 152 and thus blunts 
the downregulation of ß-catenin by GSK3 dependent phosphorylation 127;129. SGK1 further 
stimulates the expression and/or activity of a variety of channels and carriers 
33;60;122;123;140;141;152-154
 and is thus important for renal Na+ retention 61;155. Enhanced expression 
of SGK1 would be expected to foster renal Na+ retention and thus increase plasma volume. 
Accordingly, urinary Na+ excretion was indeed significantly decreased in apcMin/+ mice, a 
difference reversed by additional lack of SGK1. Mirror-like changes were observed in fecal 
Na+ excretion. Unlike renal tubular Na+ reabsorption 61;155, colonic Na+ reabsorption appears 
not to depend on SGK1 156. The fractional urinary Na+ excretion was not significantly 
different between apcMin/+ mice and apc+/+ mice, as glomerular filtration rate was similarly 
lower in apcMin/+ mice than in apc+/+ mice, a difference, however, not reversed by additional 
lack of SGK1. The observations point to a role of APC in the maintenance of glomerular 
function.  
According to the experiments with Evans blue, plasma volume was significantly larger 
in apcMin/+ mice, an effect partially blunted in apcMin/+/sgk1-/- mice. Thus, SGK1 dependent 
Na+ retention could have led to hypervolemia. Increased SGK1 expression following 
treatment with a PPARgamma agonist was similarly shown to enhance plasma volume 157, an 
effect in part dependent on SGK1.   
 
 Hypervolemia would in turn be expected to decrease aldosterone release. The opposite 
is observed, i.e. plasma aldosterone levels are significantly higher in apcMin/+ mice than in 
apc+/+ mice. Moreover, the hyperaldosteronism was not reversed but augmented by additional 
knockout of SGK1. The further increase of plasma aldosterone concentration is in line with 
the enhanced plasma aldosterone levels observed in SGK1 deficient mice, a result of impaired 
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renal Na+ retention in those animals 61;155. Clearly, the hyperaldosteronism of apcMin/+ mice is 
not due to enhanced SGK1 expression and is neither due to volume depletion nor due to 
hyperkalemia. Instead, APC-dependent signalling may influence aldosterone release more 
directly. Corticosterone levels were not significantly different between apcMin/+/sgk1-/- and 
apcMin/+ mice. Thus, unlike the increase of aldosterone levels, the increase of corticosterone 
levels may be dependent on the presence of SGK1.    
 
 Even though plasma aldosterone levels were even higher in apcMin/+/sgk1-/- mice, 
urinary Na+ excretion tended to be higher in those mice than in apcMin/+ mice, an expected 
finding in view of the known effect of SGK1 on renal tubular Na+ transport 61;155. The 
enhanced plasma aldosterone levels could further explain the increased fractional K+ 
excretion and the elevated blood pressure in apcMin/+ mice than in apc+/+ mice.  
 
 In contrast to plasma volume, body weight was not different between apcMin/+ mice 
and apc+/+ mice. Thus, the possibility was considered that the abundance of body fat was 
decreased in apcMin/+ mice. As body fat mass is correlated with leptin plasma 
concentrations158, plasma leptin levels were determined. As a result, APC deficiency was 
paralleled by marked decrease of plasma leptin concentrations, pointing to reduced body fat 
mass. Recent observations indeed point to an inhibitory effect of ß-catenin signalling on 
adipocyte differentiation 159-161. 
 
 In conclusion, plasma aldosterone and corticosterone levels, plasma volume and blood 
pressure were higher in mice carrying the defective APC gene. The effects are partially 
reversed by lack of SGK1 pointing to a role of this kinase in APC-dependent regulation of 
electrolyte homoestasis. However, SGK1 deficiency augments the effect of defective APC on 
plasma aldosterone levels, pointing to a SGK1 independent role of APC in the regulation of 
adrenal hormone release. Clearly, the signalling cascade of APC and SGK1 is more 
complicated than a simple serial chain and the present data shed some light but still do not 
clarify the final interactions. 
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 The role of SGK3 in renal phosphate handling 
 
The present observations disclose a novel function of SGK3, i.e. the stimulation of renal 
tubular phosphate transport. According to the experiments on Xenopus oocytes, coexpression 
of SGK3 leads to a marked increase in NaPiIIa activity. The in vivo relevance of SGK3 
sensitive NaPiIIa regulation is underscored by the phosphaturia of sgk3KO mice.  
 
 The phosphaturia of sgk3KO mice was not due to increased plasma phosphate 
concentrations and occurs without significant alterations of PTH plasma concentrations. The 
hormone is well known to downregulate renal phosphate transport 132, and its release is 
inhibited by enhanced plasma phosphate concentration 162. The plasma levels of 1,25(OH)2D3 
are significantly decreased in sgk3KO mice. The rate-limiting enzyme in the generation of  
1,25(OH)2D3 is the renal 1α-hydroxylase 163;164, which is stimulated by PTH 164 and cellular 
phosphate depletion 165.  
 
As 1,25(OH)2D3 is a powerful stimulator of intestinal phosphate transport 166, the 
decreased plasma 1,25(OH)2D3 concentrations may have contributed to the renal phosphate 
loss.  
 
The sgk3KO mice suffer from a subtle but significant impairment of bone mass, which 
may again be partially due to decreased formation of 1,25(OH)2D3. The hormone is known to 
counteract apoptosis of osteoblasts 167 and is thus known to enhance bone mineralization 168. 
The effect of 1,25(OH)2D3 is mediated by the phosphatidylinositol 3-kinase pathway 169, and 
may thus at least partially involve SGK3. The demineralization of bone may further be due to 
phosphate depletion, as phosphate inhibits the formation of new osteoclasts and stimulates 
apoptosis of mature osteoclasts 170. The present observations do not rule out the participation 
of further mechanisms. For instance, SGK3 shares several functions with Akt2/PKBß 171, 
which may confer survival of osteoblasts 172 and osteoclasts 173;174.  
 
In conclusion, the present observations reveal a novel function of SGK3, i.e. its 
involvement in the regulation of 1,25(OH)2D3 plasma concentration, renal phosphate 
excretion and mineralization of bone. 
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ABBREVIATIONS 
ACE Angiotensin converting enzyme 
ADH  Anti Diuretic hormone 
ADP  Adenosine diphosphate 
APC  Adenomatous polyposis coli 
ASDN Aldosterone sensitive distal nephron 
ATP  Adenosine triphosphate 
AVP  Arginine vasopressin 
BBM  Brush border membrane 
BIO  6-bromoindirubin-3´-oxime 
BW                Body weight  
CaCl2 Calcium chloride  
CCD  Cortical collecting duct 
CISK Cytokine independent survival kinase 
Dexa    Dexamethasone  
dL    decilitre  
DOCA   Deoxycorticosterone acetate 
ECF  Extracellular fluid  
ENaC  Epithelial sodium channel 
FAP  Familial adenomatous polyposis 
FE   Fractional excretion  
GFR  Glomerular filtration rate 
GS   Glycogen synthase  
GSK3 Glycogen synthase kinase-3 
HEPES N-2-Hydroxyethylpiperazine-N’-2-ethanesulfonic acid 
IGF-1 Insulin like growth factor-1 
Ins Insulin  
KCl  Potassium Chloride  
MAPK Mitogen-activated protein kinase 
MCD Medullary collecting duct 
mg milligram  
MgCl2 Magnesium Chloride 
Min minute  
MR Mineralocorticoid receptor 
NaCl Sodium Chloride  
NaPi Sodium-phosphate cotranspoter 
Ng nanogram  
NHERF2   Sodium-hydrogen exchanger regulatory factor 2 
Nmol nanomoles  
PBS Phosphate buffered saline 
PDK1 Phosphoinositide dependent kinase 1 
pg Picogram  
Pi  Phosphate  
PI3K  Phosphatidylinositide-3-kinase 
PKA   Protein kinase A  
PKB  Protein kinase B  
PKC  Protein kinase C  
PKG  Protein kinase G  
PTH  Parathyroid hormone 
ROMK  Renal outer medullary potassium channel 
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SD Standard diet   
SGK  Serum and glucocorticoid inducible kinase 
µg  microgram  
µL microlitre  
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